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Rational combinatorial targeted therapies for cancer are likely required to 
achieve potent durable responses. We mapped the interactome of a tumor-
enriched isoform of Hsp90 (teHsp90), using a pharmacoproteomics approach 
trapping teHsp90 with the small molecule PU-H71. This strategy yielded 
enrichment of the proximal B cell receptor (BCR) signalosome. In functional 
assays we identified a novel mechanism for teHsp90 in facilitating BCR 
signaling dynamics by enabling phosphorylation of key BCR signalosome 
components including SYK and BTK. Consequently, PU-H71 attenuated BCR 
signaling, calcium flux and NF-κB signaling, ultimately leading to growth arrest 
in BCR-dependent ABC DLBCL cells. Combined exposure to PU-H71 and 
BCR pathway inhibitors, most notably ibrutinib, resulted in more potent 
suppression of BCR signaling than either drug alone in ABC DLBCL cell lines. 
PU-H71 combined with ibrutinib correspondingly induced synergistic killing of 
ABC DLBCL cell lines, primary human specimens ex vivo, and lymphoma 
xenografts in vivo, without significant toxicity. Pharmacoproteome driven 
rational combination therapy thus provides the basis for more potent BCR-
directed therapy for ABC-DBLCL patients. 
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teHsp90 inhibition induces broad attenuation of lateral pathways that 
contribute to the greater BCR signaling network and DLBCL survival such as 
PI3K/AKT and ERK signaling, likely contributing to the synergistic growth 
inhibition induced by the PU-H71-ibrutinib combination treatment. In viability 
assays of many different combinations of BCR pathway inhibitors in ABC 
DLBCL cell lines, we observed differential combination growth inhibition effects 
that suggest general principles required for rational combination treatment 
design. Namely, inhibition of lateral pathways within a signaling network 
induces maximal synergistic growth arrest. 
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CHAPTER ONE 
INTRODUCTION 
 
Cancer is not a single disease; rather, it is a collection of molecularly distinct 
illnesses united by shared traits. Most subtypes arise from numerous 
molecular lesions linked to either somatic mutations or the hijacking of normal 
proteins by tumors resulting in non-oncogene addiction. Targeted therapies 
against these proteins and pathways administered as single agents are 
unlikely to be curative due to the genetic complexity, clonal heterogeneity and 
development of resistance of most tumors. The signaling pathways that direct 
the abnormal cellular growth of cancer contain functional redundancy, further 
complicating efforts to therapeutically target these malignancies. In order to 
improve treatment for cancer patients, a better understanding of the complex 
signaling pathways governing tumor growth is required. Greater suppression 
of these pathways may be achieved through the design of rational 
combinations of targeted agents that affect parallel or complementary 
pathways, leading to tumor eradication.  
 
1. Heat shock protein 90 (Hsp90) 
 
Structure and Function 
Heat shock protein 90 (Hsp90) is a ubiquitously expressed molecular 
chaperone that assists the proper folding, assembly and transportation of 
hundreds of cellular proteins – collectively known as “clients” – involved in 
numerous processes including cell growth, proliferation and survival (1). 
Hsp90 is a conformationally flexible protein dimer; each monomer contains a 
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C-terminal protein-binding region and an amino-terminal ATP-binding pocket 
linked by a middle domain. With the assistance of certain co-chaperones, 
Hsp90 hydrolyzes ATP to propel the Hsp90-chaperone cycle in which client 
proteins are bound in an inactive state, chaperoned for proper folding, and 
ultimately released (2) (Figure 1.1).  
Hsp90 is expressed constitutively, but can also be induced upon cellular 
stress, such as heat shock, in order to maintain the function of damaged 
 
Figure 1.1 The Hsp90 chaperone cycle. Clockwise from top left, ATP 
binding to the N-termial ATPase domain (NTD) of Hsp90 induces a 
conformational change and NTD dimerization, forming the closed Hsp90 dimer 
necessary for ATP hydrolysis. Inactive client proteins bind mostly to the middle 
domain of Hsp90 and are conformationally activated as Hsp90 advances 
through the ATPase cycle that is facilitated or inhibited by certain cofactors 
including AHA1, HOP, CDC37 and p23. CTD, C-terminal domain. Adapted 
from (2). 	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proteins. This function may have played a role in the evolutionary process, 
allowing cells to tolerate an accumulation of inherent genetic mutations (3, 4). 
Similarly, because it sustains the viability of cells under transforming pressure, 
Hsp90 plays an important role in maintaining the cancer phenotype. 
 
The role of Hsp90 in cancer  
Six hallmark characteristics are shared by most if not all cancers: (i) self-
sufficiency in growth signaling, (ii) insensitivity to anti-growth signaling, (iii) 
ability to evade apoptosis, (iv) limitless replicative potential, (v) sustained 
angiogenesis, and (vi) tissue invasion and metastasis (5). Hsp90 regulates 
proteins and pathways involved in each of these capabilities (Figure 1.2) 
Hsp90 also maintains the functional stability of damaged proteins, especially in 
cells under transformative pressure. It is therefore not surprising that cancer 
cells often hijack this mechanism to promote their malignant phenotype. 
Indeed, Hsp90 is highly expressed in most tumor cells. Moreover, Hsp90 has 
been shown to regulate nearly every protein that is involved in cell-specific 
oncogenic processes (6).  
 
Hsp90 inhibition 
Because Hsp90 maintains the stability and activity of many oncogenic client 
proteins that cause and maintain malignant phenotypes, it is an attractive 
therapeutic target. Several inhibitors of the N-terminal ATPase pocket of 
Hsp90 have been discovered and developed. These compounds block ATP 
from binding Hsp90, locking the chaperone and preventing the conformational 
changes necessary for the Hsp90 chaperone cycle to proceed. Interruption of 
chaperone cycling induces targeting of client proteins to the proteasome 
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where they are degraded (6-8). In a cancer cell, degradation of the oncogenic 
proteins chaperoned by Hsp90 can result in decreased proliferation or cell 
death.  
 
The first Hsp90 inhibitors discovered were N-terminal ATP pocket binders, 
including natural products, such as ansamycins (geldanamycin (GM), 17-
allylamino-17-demethoxygeldanamycin (17-AAG), and 17-dimethylaminoethyl-
amino-17-demethoxy-geldanamycin (17DMAG) (9-11) and radicicols (RDs)  
(RD (12), cycloproparadicicol (13), and pochonin D (14)). Two of these early 
Hsp90 inhibitors, 17AAG and 17DMAG, were the first to enter the clinic. 
Rational design or high-throughput screening was used to discover later 
	  
Figure 1.2 Hsp90 chaperones proteins that establish each of the six 
hallmarks of cancer (Adapted from 1, 5).	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Hsp90 N-terminal inhibitors. These include purine-scaffold derivatives (PU-
class) (15) and other scaffolds types (16).  
 
Compounds that bind to the C-terminal and middle domains of Hsp90 and 
disrupt its chaperone function have also been described. Novobiocin, a 
coumarin-containing DNA gyrase inhibitor, weakly binds the C-terminal 
domain of Hsp90 (17) that binds a second ATP molecule after the N-terminal 
pocket has bound either ATP or an inhibitor. The C-terminal ATP binding site 
may regulate the N-terminal ATPase activity, thereby affecting the Hsp90 
chaperone cycle (17, 18). 
 
Agents that interfere with the binding of Hsp90 and its co-chaperones or client 
proteins have also been described. Shepherdin, a peptidomimetic of  minimal 
span that retains Hsp90 inhibitory activity of the anti-apoptotic and mitotic 
regulator survivin, binds the ATP pocket of Hsp90, causing destabilization of 
client proteins (19). 
 
Inhibition of histone deacetylases (HDACs) can induce Hsp90 acetylation, 
which prevents its ability to bind ATP, which blocks chaperone function and 
induces degradation of client proteins. This effect has been shown using 
different HDAC inhibitors including the depsipeptide FR-901228 (20), LAQ824 
(Nimmanapalli cancer research 2003), LBH589 (21), suberoilanilide 
hydroxamic acid (22) and by inhibition of HDAC6 by specific short-interfering 
RNA (siRNA) (22, 23). Hsp90 chaperone function is also dependent on 
several post-translational modifications including phosphorylation (24, 25), 
acetylation (23), ubiquitylation (26) and S-nitrosylation (27). Indirect inhibition 
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of Hsp90 via modulation of its post-translational modifications may be another 
route to therapeutically target Hsp90. 
 
Hsp90 is expressed in normal cells, comprising 1-2% of total cellular protein, 
where it assists the folding of hundreds of proteins including kinases, 
transcription factors and receptors. Constitutive Hsp90 genetic knockout in 
eukaryotes is lethal (28), calling into question the therapeutic window required 
for Hsp90 to be viable drug target. However, it was the discovery and 
investigation of Hsp90-selective compounds that revealed principles that 
validated Hsp90 as a bona fide target in cancer. Several classes of these 
inhibitors bind selectively to Hsp90 in tumor cells (19, 29-32). Importantly, 
cancer cells are significantly more sensitive to Hsp90 inhibition than their 
normal counterparts (12, 19, 29-34). Further, Hsp90 inhibitors have anticancer 
effects in animal models at nontoxic doses (19, 32, 33, 35, 36). Some of these 
inhibitors accumulate in animal model tumors while exhibiting rapid clearance 
from the blood and normal tissues (11, 29, 32, 37-39). 
 
Tumor selectivity of Hsp90 inhibitors 
The astonishing tumor selectivity of Hsp90 inhibitors remains to be fully 
explained, but data in the field has led to several hypotheses. One idea is that 
Hsp90 exists in a higher affinity state in cancer cells (30). This notion was first 
supported by experiments showing that 17AAG exhibits a 100-fold difference 
in affinity between Hsp90 in transformed cells and that of normal cells (30). 
Reports with other Hsp90 inhibitors of the PU-class (31, 32) as well as 
shepherdin (19) confirm this finding. In vivo studies demonstrating extensive 
retention of Hsp90 inhibitors in tumors while being rapidly cleared from blood 
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also support this hypothesis. The PU-class Hsp90 inhibitor PU24Cl (32) was 
the first agent to demonstrate this behavior, accumulating at pharmacologically 
relevant doses in MCF7 xenograft tumors. Studies showing similar results 
were reported with 17DMAG in MDA-MB-231 xenograft tumors (39), 17AAG in 
human ovarian xenograft tumors (37), and IPI-504, the reduced form of 
17AAG in a multiple myeloma xenograft model (40). Hsp90 inhibitors of 
several classes exhibit the phenomenon of tumor accumulation, which may be 
due to the higher affinity state of tumor Hsp90. 
 
A second hypothesis to explain the tumor selectivity of Hsp90 inhibitors is the 
post-translational modification status of Hsp90 (41). Hsp90 is modified by 
serine-, threonine- and tyrosine-phosphorylation (42-45). Phosphorylation of 
Hsp90 results in loss of binding to client proteins (24, 46). As discussed 
above, acetylation of Hsp90 may be required for chaperone cycle function. 
Studies in HDAC6-deficient cells show that the glucocorticoid receptor (GR), a 
client of Hsp90, has diminished ligand binding, nuclear translocation and gene 
activation (47). More, cytosolic Hsp90 from HDAC-knockdown cells has less 
ATP-binding affinity and cannot assemble into a complex with GR (23). 
Acetylated Hsp90 shows decreased association with other clients including 
HER2, mutant p53, Raf-1 and androgen receptor (48, 49). S-nitrosylation of 
Hsp90 has also been shown to inhibit its chaperone activity (27). Hsp90 is 
ubiquitinated at several residues by the ubiquitin ligase C-terminus of Hsc70 
interacting protein (CHIP) (50), targeting it to the proteasome (51).  Protein 
methyltransferases have been identified as Hsp90 interacting proteins (52) 
and Hsp90 lysine methylation by SMYD2 has been described (53, 54). These 
post-translational modifications may play a role in Hsp90 activity and affinity 
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for inhibitors. Similar to post-translational modification, the interaction of Hsp90 
with certain sets of co-chaperones (30, 55-59) and the post-translational 
modifications of these co-chaperones (57, 60-64) may play a role in the 
enhanced affinity of tumor Hsp90 for inhibitors.  
 
Finally, the intrinsic nature and function of Hsp90 may provide the solution. 
Hsp90 and its co-chaperones can be genetically deregulated in cancer cells 
(65-68). However, protein expression is unlikely to account for the ability of 
Hsp90 and its co-chaperones to regulate such an astonishingly diverse 
repertoire of stressed proteomes (67, 69-71). In normal cells, Hsp90 
comprises 1-2% of cellular protein, and in tumor cells, this amount increases 
to 4-6%. In the in vivo Hsp90 inhibitor experiments described above, inhibitors 
are administered in great excess (50 – 200 mg/kg) of the amount of Hsp90 
protein (~500 μM) found in the tumors. At these concentrations, the drugs 
inhibit tumor growth, but only 0.5-50% of drug is retained in the tumors, 
suggesting that only a small fraction of total Hsp90 binding sites are bound by 
inhibitor (72). These calculations suggest that there exists a pool of Hsp90 in a 
high-affinity conformation that specifically chaperones the small fraction of 
cellular proteins that drive the malignant phenotype. 
 
Taken together, these complementary hypotheses illustrate a scenario with 
two states of Hsp90. “Latent state” Hsp90, found in normal cells, (and to a 
lesser extent in stressed or cancer cells,) chaperones normal proteins and 
exhibits low-affinity for ATP as well as Hsp90 inhibitors. Cancer cells or other 
chronically stressed cells, preferentially contain “activated state” Hsp90, which 
is found in megacomplexes with co-chaperones and has a high affinity for 
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client proteins, which are often involved in driving and regulating the malignant 
phenotype (Figure 1.3). Under transforming pressure, such as mutation, 
activation or other stress, Hsp90 client proteins in cancer cells develop an 
increased requirement for chaperoning. This tumor-enriched Hsp90 (teHsp90) 
has a higher affinity for inhibitors, which may explain the therapeutic window of 
this class of drugs (72).  
 
Hsp90 complexes in cancer cells are not comprised of only activated state 
Hsp90. Rather, cancer cells contain both a pool of latent state or 
“housekeeping Hsp90” with low affinity for Hsp90 inhibitors in addition to the 
activated or “oncogenic Hsp90” pool which chaperones the proteome required 
for the malignant phenotype (58). Exactly how these two fractions differ 
remains to be resolved, but may be explained by one or more of the above 
	  
Figure 1.3 The two states of Hsp90. Tumor cells preferentially contain 
Hsp90 in higher-order multi-chaperone complexes. This tumor-enriched Hsp90 
(teHsp90) has a higher affinity for Hsp90 inhibitors than normal tissues, which 
contain latent, uncomplexed Hsp90. Modified from (72). 	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hypotheses. This difference, however, provides the rationale for targeting 
Hsp90 in cancer cells. 
 
Hsp90 inhibitors as chemical tools 
While the definitive source of the tumor selectivity of Hsp90 inhibitors has yet 
to be elucidated, this principle can be exploited to identify tumor specific 
teHsp90 client proteomes. By immobilizing Hsp90 inhibitors on solid supports, 
these compounds can be used as chemical tools to affinity purify cell-specific 
teHsp90 megacomplexes. This method allows not only for the identification of 
the cell-specific teHsp90 proteome, but also the investigation of the molecular 
mechanisms by which teHsp90 regulates specific subtypes of cancer. 
 
This approach goes back to the first Hsp90 inhibitor, geldanamycin. Originally 
identified in a screen of compounds that could revert the phenotype of cells 
transformed with the v-src oncogene, it was eventually shown that the 
tumoricidal activity of GM was not related to src-inhibition (34). Rather, using 
solid phase immobilized GM affinity precipitation, Hsp90 was identified as the 
molecular target of GM, highlighting the role of Hsp90 in oncogenic processes 
(73).  
 
In fact, this method (Figure 1.4) was used to describe the oncogenic pool of 
teHsp90-chaperoned complexes in cancer cells. Moulick et al (58) used PU-
H71, a purine-scaffold small molecule inhibitor of Hsp90, conjugated to 
agarose beads to chemically precipitate teHsp90 in the breast cancer cell line 
MDA-MB-468. After seven sequential chemical precipitations, the fraction of 
Hsp90 bound to PU-H71 was drastically reduced as shown by immunoblot for 
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Hsp90 (58). Although the pool of Hsp90 bound by these compounds was 
nearly depleted, immunoprecipitation of the remaining supernatant with an 
antibody to Hsp90 effectively isolated substantial amounts of Hsp90, which 
showed no depletion after three sequential immunoprecipitations (58). This 
finding demonstrates that PU-H71 interacts with a specific fraction of Hsp90 in 
cancer cells. Along these lines, the authors went on to show that some Hsp90 
inhibitors can deplete cancer cells of Hsp90-chaperoned oncoproteins. Using 
extracts from the BCR-ABL+ CML cell line K562, the authors first 
demonstrated that an antibody to Hsp90 co-immunoprecipitates both BCR-
ABL and its normal counterpart c-Abl, and that both of these proteins are 
	  
Figure 1.4 PU-H71 chemical precipitation. Following cell lysis, protein 
extracts are precleared, then incubated with agarose beads conjugated to an 
Hsp90 inert chemical (control) or PU-H71 beads to precipitate teHsp90 
complexes. Beads are washed, complexes are eluted by boiling in SDS 
loading buffer and resolved by SDS PAGE followed by mass spectrometry 
(unknown clients) or immunoblotting (known/hypothesized clients). 
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present in the remaining supernatant. By contrast, chemical precipitation of 
teHsp90 complexes with PU-H71 beads preferentially sequestered BCR-ABL, 
while the remaining supernatant contained only Abl, furthering the notion that 
the pool of PU-H71-bound teHsp90 can be depleted (58). To further 
demonstrate this, the authors performed sequential chemical precipitations 
using PU-H71 beads followed by immunoprecipitation with an antibody to 
Hsp90 of the remaining supernatant. Sequential PU-H71 chemical 
precipitations depleted cell extracts of BCR-ABL to the extent that the final 
immunoprecipitation isolated only Abl and not BCR-ABL, though this antibody 
was previously shown to co-immunoprecipitate equal amount of both proteins 
(58). The authors observed similar results for the synthetic Hsp90 inhibitor 
SNX-2112, while NVP-AUY922 behaved like the Hsp90 antibody. GM beads 
were less efficient at co-precipitating BCR-ABL. The authors also showed that 
the PU-H71-bound fraction of teHsp90 in K562 cells co-precipitates with the 
chaperones Hsp70, Hsp40 and HOP (58). This data clearly shows that 
teHsp90 inhibitors interact with a restricted fraction of Hsp90 that preferentially 
chaperones oncoproteins. Finally, the authors used PU-H71 chemical 
precipitation combined with mass spectrometry to identify the aberrant 
signalosome of CML cells (58). From these experiments, the authors identified 
the STAT pathway as clients of Hsp90 and described a novel role of teHsp90 
in regulating STAT activation in CML. 
 
In a collaboration project, work from our laboratory demonstrates that teHsp90 
chaperones viral proteins that drive Kaposi’s sarcoma-associated herpesvirus 
(KSHV) positive primary effusion lymphomas (PELs). Using PU-H71 chemical 
precipitation, both vFLIP, the viral homolog of cellular FLIP (cFLIP), and its 
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downstream target IKKγ were identified as clients of teHSP90 in four KSHV+ 
PEL cell lines (Figure 1.5) (74). Together, vFLIP and and IKKγ form the vFLIP 
signalosome which induces NF-κB activity, leading to anti-apoptotic and pro-
proliferative signaling in PEL cells (75). Importantly, PU-H71-bound teHsp90 
associates only with cFLIPL (long isoform) and not cFLIPS (short isoform) (74). 
Though vFLIP is more closely structurally related to cFLIPS, it is the long 
isoform of cFLIP that induces NF-κB activity (75). This finding confirms that 
PU-H71 selectively precipitates oncocomplexes. Taken together, these studies 
clearly demonstrate the usefulness of Hsp90 inhibitors, specifically the purine 
scaffold inhibitor PU-H71, as chemical tools to probe known and unknown 
client oncoproteins of Hsp90 to reveal underlying mechanisms of teHsp90 
regulation of cancer. 
 
Hsp90 inhibitors target oncoproteins 
While the exact mechanism of the tumor selectivity of Hsp90 inhibitors 
remains to be elucidated, teHsp90 selectively chaperones those proteins 
required for cancer cell survival, many of which are mutated or chimeric. As a 
	  
Figure 1.5 teHsp90 chaperones the vFLIP signalosome in KSHV+ PELs. 
Immunoblots of PU-H71-bead (PU), but not control-bead (CO) pulldowns in 
KSHV+ PEL cell lines recognized vFLIP and IKKγ. IBL1, a KSHV- cell line, was 
included as a negative control for vFLIP (74).	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result, these oncoproteins are degraded upon teHsp90 inhibition. For example, 
anaplastic large cell lymphoma is characterized by the expression of the 
constitutively active chimeric protein NPM-ALK, a fusion of the nucleophosmin 
(NPM) and the membrane receptor anaplastic lymphoma kinase (ALK). NPM-
ALK is a client of Hsp90 and is destabilized and degraded in cells exposed to 
Hsp90 inhibitors (76). Exposure to Hsp90 inhibitors causes selective apoptosis 
in acute myeloid leukemia (AML) cells harboring mutant FLT3 receptor 
tyrosine kinase (77) through rapid loss of FLT3 activity as well as several of its 
downstream targets. The BCR-ABL fusion protein results from a chromosomal 
abnormality associated with chronic myelogenous leukemia (CML) and is a 
client of Hsp90 (58, 78). Mutations in the c-kit proto-oncogene cause 
constitutive activity of the KIT protein associated with gastrointestinal stromal 
tumors (GIST). This activity as well as activity of downstream effector 
molecules is abrogated upon exposure to Hsp90 inhibition (79). Mutant B-Raf 
often associated with melanomas is highly dependent on Hsp90 and 
accordingly sensitive to Hsp90 inhibition (80, 81). Prostate cancer is often 
driven by overexpression, mutation or post-translational modification of the 
androgen receptor (AR), even in the presence of anti-androgens. AR is an 
Hsp90 client whose expression is decreased with Hsp90 inhibition in a 
prostate cancer cell line (82). Moreover, Hsp90 inhibition prevents nuclear 
translocation of ligand-bound AR and diminishes transcriptional activity of 
nuclear AR (36). The BCL6 transcription factor gene is often translocated and 
hypermutated in diffuse large B cell lymphoma (DLBCL). BCL6 is chaperoned 
by Hsp90 and degraded upon Hsp90 inhibition (38). Just as teHsp90 
selectively chaperones oncogenic proteins, teHsp90 inhibition disrupts the 
function and stability of these client onocoproteins in a variety of tumor types. 
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Hsp90 inhibition overcomes resistance to targeted therapies of Hsp90 
client proteins 
Many targeted therapies for cancer are aimed at proteins that drive the 
malignant phenotype either through mutation or non-oncogene addiction. One 
of the major deficits of single agent targeted therapy is the acquisition of 
resistance either through mutation of the drug binding site or upregulation of a 
compensatory molecule or pathway. Many of these targeted oncoproteins are 
clients of Hsp90, and cells that have become resistant to first line therapeutics 
targeted to these molecules are sensitive to Hsp90 inhibitors. For example, 
imatinib is a small molecule inhibitor of the BCR-ABL fusion protein that drives 
Philadelphia chromosome-positive leukemia (83). These cells can acquire 
imatinib resistance through mutations in the BCR-ABL kinase domain or gene 
amplification (84), but have been shown to increase or maintain their 
dependence on Hsp90 and sensitivity to Hsp90 inhibition (85). In tumors with 
MET gene amplifications, c-Met inhibition only causes a modest decrease in 
downstream signaling, but 17AAG destabilizes c-Met protein and also causes 
significant disruption of downstream signaling (86). Tumor xenografts 
harboring MET-amplifications that are both sensitive and resistant to c-Met 
inhibitors are sensitive to Hsp90 inhibtion (87). Non-small cell lung cancer 
(NSCLC) cells acquire resistance to the tyrosine kinase inhibitors gefinitib and 
erlotinib through a T790M mutation in EGFR. Hsp90 inhibition in these cells 
reduces EGFR expression levels as well as downstream and compensatory 
signaling (88). Some EGFR mutations are intrinsically resistant to gefitinib and 
erlotinib, but Hsp90 inhibitors destabilize these mutants as well as 
downstream signaling, resulting in decreased tumor cell viability (89). Other 
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NSCLC tumors express the EML4-ALK fusion oncogene and initially respond 
to the tyrosine kinase inhibitor crizotinib, which targets ALK. These tumors 
gain resistance through gene amplifications and a kinase domain mutation, but 
resistant cells are highly sensitive to 17AAG (90). Breast cancer patients with 
amplification of the HER2 oncogene are effectively treated with trastuzumab, a 
fully humanized monoclonal antibody to HER2, until resistance emerges 
through truncation of HER2, dimerization with other receptor tyrosine kinases, 
activation of downstream kinases or deletion of downstream tumor 
suppressors. HER2-positive cell lines with intrinsic or acquired resistance to 
trastuzumab are sensitive to Hsp90 inhibition, and show degradation of HER2 
as well as inhibition of downstream signaling (91). Triple negative breast 
cancers, which do not express HER2, estrogen receptors or progesterone 
receptors, are insensitive to most targeted therapies. They are, however, 
sensitive to Hsp90 inhibition because of loss of multiple signaling pathways, 
causing decreased proliferation and induction of apoptosis in cellular and 
animal models (92). 
 
Hsp90 inhibitors can overcome resistance to other non-targeted therapies as 
well. For example, mantle cell lymphoma is effectively treated with the 
proteasome inhibitor bortezomib. Resistance emerges quickly through 
upregulation of the co-chaperone Grp78, which depends on Hsp90 
chaperoning activity. Resistant cells treated with bortezomib combined with 
Hsp90 inhibitors disrupt the Grp78/Hsp90 complex and cause apoptosis in 
vitro and in vivo (93).  
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Hsp90 inhibitors in the clinic 
As discussed, teHsp90 is a promising therapeutic target for cancer. As such, 
many inhibitors have been tested in the clinic. Geldanamycin, an ansamycin 
and the first Hsp90 inhibitor, displayed poor solubility in addition to significant 
hepatotoxicity in animals, preventing its clinical evaluation (94). 17AAG, a 
derivative of GM with similar biological activity but an improved toxicity profile 
(10) was the first to enter the clinic. In a phase II clinical trial of women with 
trastuzumab-resistant HER2+ breast cancer, the addition of 17AAG caused 
significant response (8). Other trials of 17AAG plus bortezomib in 
relapsed/refractory multiple myeloma also demonstrated promising results 
(11). A more water soluble derivative of 17AAG, 17-desmethoxy-17-N,N-
dimethylaminoethylaminogeldanamycin (17DMAG), was synthesized by the 
NCI. This compound was explored in various trials of prostate cancer, 
melanoma, breast cancer, and AML (92, 93). Though 17DMAG was well-
tolerated and showed some clinical activity, this research program was 
terminated possibly due to competition from upcoming second generation 
inhibitors as well as the difficult synthesis of 17AAG (95). Infinity 
pharmaceuticals developed a water-soluble salt of 17AAG called IPI-504, the 
reduced hydroquinone of 17AAG. In vivo, these compounds exist in a redox 
equilibrium. The quinone of 17AAG may have been the source of the 
compound’s hepatotoxicity; reduction to a hydroquinone resulted in the less 
toxic, more potent IPI-504. Hsp90 inhibitors from the purine class have also 
entered the clinic, including BIIB021, the second purine scaffold-based Hsp90 
inhibitor developed by Biogen Idec, CUDC-305 developed by Curis, and PU-
H71 developed at Memorial Sloan Kettering (96). Several Hsp90 inhibitors 
from the resorcinol family have also been evaluated clinically. STA-9090 
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(ganetespib) developed by Synta Pharmaceuticals showed activity in clinical 
trials of advanced solid tumors as well as NSCLC patients. AUY922 developed 
by Novartis has shown clinical activity in breast cancer and GIST and is 
currently being evaluated in DLBCL patients (96). 
 
Hsp90 inhibition as a platform for combination therapies 
The tumor selectivity of Hsp90 inhibitors created the basis for therapeutically 
targeting teHsp90 in cancer. Another attractive feature of Hsp90 as a 
therapeutic target is its broad relevance to different types of cancer regardless 
of genetic background. Because teHsp90 chaperones a plethora of different 
oncoproteins in multiple signaling pathways, it stands to reason that Hsp90 
inhibition constitutes a simultaneous attack on multiple nodes of a cancer cell’s 
signaling network. Hsp90 inhibition can break or at least weaken concurrently 
multiple oncogenic signaling pathways. This feature is highly attractive 
because single agent therapy is unlikely to be curative in cancer due to 
acquisition of resistance, tumor heterogeneity and redundant signaling 
pathways. All of these issues can be addressed, at least partially, by Hsp90 
inhibition, because Hsp90 inhibitors target multiple proteins and pathways at 
the same time. As discussed, Hsp90 inhibition can overcome de novo and 
acquired resistance to targeted therapies in several types of cancer. In this 
regard, Hsp90 inhibition serves as an optimal platform for combination with 
targeted therapies against Hsp90 client proteins. This approach could show 
increased anti-tumor effect through maximal suppression of critical signaling 
nodes by inhibiting directly with targeted inhibitors in addition to Hsp90 
inhibition. Furthermore, as the client protein is destabilized and degraded in 
the presence of Hsp90 inhibition, synergistic antitumor effects may be 
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observed, as less of the targeted agent is required to hit its target. The 
identification of druggable teHsp90 client proteins and pathways specifically 
required for cancer cell survival may highlight rational targets for combinatorial 
therapies for cancer. These combination treatments may evade the 
emergence of resistance due to the broad dampening of cellular signaling that 
results from Hsp90 inhibition. 
 
Diffuse large B cell lymphoma (DLBCL) 
 
B cell development 
Many of the key processes required for normal B-cell differentiation and 
survival also contribute to the transformed phenotype of B-cell lymphomas. B 
cell receptor (BCR) expression on the cell surface is the hallmark of B cells. 
This receptor comprises two heavy-chain and two light-chain immunoglobulin 
(Ig) polypeptides covalently linked by disulfide bridges. The Igα/Igß 
(CD79A/CD79B) heterodimer, the signaling moiety of the BCR, contains 
cytoplasmic immunoreceptor tyrosine activation motifs (ITAMs) that transmit 
signals to downstream signaling effectors of the BCR pathway upon BCR 
crosslinking. 
 
Early B-cell development, which occurs in the bone marrow, is the process by 
which B cell precursors rearrange the Ig heavy- and light-chain gene loci to 
produce a functional surface BCR (97). Accordingly, each step of this 
progression is characterized by the specific structure of the BCR. The Ig 
molecules contain variable and constant regions, which bind to antigen and 
mediate downstream signaling, respectively. Pre-B cells rearrange the genetic 
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loci that encode the heavy- and light-chain regions of the variable regions 
through V(D)J recombination. In this process the 50 VH, 27 DH, and 6 JH gene 
segments are joined to produce the heavy-chain variable region. The variety of 
gene segments available for rearrangement ensures the generation of a 
diverse repertoire of VH gene rearrangements. DH-JH rearrangements occur 
first, followed by VH-DHJH rearrangements. If productive, this process 
culminates in expression of a pre-B-cell receptor. Pre-B cells then carry out 
rearrangements of the light-chain from VL and JL gene segments. Ultimately 
the rearranged VDJ is joined to an Ig constant region (98). Following this 
process, pre-B cells that express a functional BCR differentiate into mature B 
cells and leave the bone marrow; those that do not undergo apoptosis (98). 
 
Following VDJ recombination, mature B cells are activated by antigen binding 
of the BCR during immune response. In T-cell-dependent immune responses, 
mature B cells enter transient structures called germinal centers that are found 
in secondary lymphoid organs such as the lymph nodes. The histological 
appearance of these structures divides the germinal center into two distinct 
sections: the dark zone, which contains large proliferating B cells 
(centroblasts), and the light zone, which contains smaller, non-dividing B cells 
(centrocytes). Germinal center formation begins when a naïve mature B cell in 
the B cell follicle encounters antigen. Once in the germinal center, B cells 
enter the dark zone where they undergo massive clonal expansion (99). These 
rapidly proliferating cells undergo somatic hypermutation of the genes of the Ig 
variable region in an attempt to further increase the affinity of the BCR for 
antigen (100). Disadvantageous mutations that lead to reduced affinity of the 
BCR for antigen causes cells to undergo apoptosis. The few germinal center B 
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cells with increased affinity for antigen are positively selected for survival by 
CD4+ T cells and follicular dendritic cells in the light zone (101). 
 
After somatic hypermutation, cells undergo a process of class switching where 
the constant region of the heavy chain is replaced with that of another Ig gene, 
such as IgM being replaced by IgG. Finally, these germinal center B cells 
differentiate into memory B cells or plasma cells and leave the germinal center 
microenvironment (97). This process is illustrated in Figure 1.6.   
 
The considerable genotoxic stress associated with the processes of B cell 
development is tightly regulated. The BCL6 (B cell lymphoma 6) transcription 
factor is a critical transcriptional regulator of germinal center formation and 
antibody affinity maturation. BCL6 knockout mice fail to develop germinal 
centers and lack antibody affinity maturation, suggesting its essential role for 
these processes (102, 103). In fact, BCL6 is upregulated by both B and T cells 
in the B cell follicle following antigenic stimulation of naïve B cells (104, 105). 
The transcriptional program of BCL6 in the germinal center enables GC B cells 
to tolerate this level of damage. By repressing expression of genes involved in 
cell cycle arrest, apoptosis and DNA damage response such as TP53, 
CDKN1A, ATR, CHK1 and ATM (106-110). BCL6 allows GC B cells to 
undergo rapid proliferation despite an excess of DNA damage including 
double-stranded breaks that normally causes apoptosis. In order to prevent 
premature activation of GC B cells by T cells, BCL6 also represses genes 
involved in B cell activation such as CD69, CD44, CD23b and NF-κB1 (111-
113). BCL6 also maintains the germinal center phenotype by blocking terminal 
differentiation of GC B cells to plasma cells by repressing PRDM1 (113). BCL6 
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downregulation is required for centroblasts to differentiate into centrocytes and 
ultimately plasma cells. Following antigen engagement of the BCR, mitogen-
activated protein kinases (MAPKs) phosphorylate BCL6, leading to its 
ubiquitin-mediated proteasomal degradation (114). Follicular helper T cells 
expressing CD40 ligand interact with GC B cells, inducing CD40 signaling, 
leading to NF-κB-mediated activation of IRF4. Binding of the BCL6 promoter 
by IRF4 results in downregulation of BCL6 (115). Overall, BCL6 is a master 
transcriptional regulator of the germinal center program. 
 
Non-Hodgkin’s lymphoma (NHL) is the seventh most common type of cancer. 
This group of about 15 different malignancies can be formed from either B-
cells or T-cells, the most common of which is diffuse large B cell lymphoma 
(DLBCL). In 2014, the NIH estimates over 70,000 new cases of DLBCL 
resulting in almost 19,000 deaths (www.cancer.gov). Historically, DLBCL 
patients exhibited clinical heterogeneity, with only about 40% of patients 
responding to therapy (116).  
 
Because stages of B cell development are characterized by specific structures 
of the BCR and expression of differentiation markers, examination of these 
features can be used to distinguish the cells of origin of different subtypes of B 
cell lymphomas (117, 118). In order to improve diagnosis and treatment of 
DLBCL, many studies have attempted to classify this molecularly 
heterogeneous disease. One gene expression profiling study divided DLBCL 
into two major subtypes (119). Germinal center B cell like (GCB) DLBCL can 
be characterized by the expression of genes important for germinal center 
differentiation including BCL6 and CD10, whereas activated B cell like (ABC) 
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DLBCL is distinguished by a gene expression profile resembling that of 
activated peripheral blood B cells. The NF-κB pathway is more active and 
often mutated in ABC DLBCL (119). Each of these subtypes differs not only in 
gene expression and apparent cell of origin, but also in the process of 
malignant transformation, clinical presentation, chemotherapy cure rates and 
response to targeted therapies, making each a distinct cancer. 
 
These prospective classifications were made using patient samples and while 
they have advanced the understanding of the molecular mechanisms 
underlying DLBLCL to a degree, they have not been the final answer for 
diagnosis or treatment of patients. Until these details are better understood, 
treatments cannot be individually tailored. Because patient samples are 
comprised of heterogeneous populations of cells and tumor microenvironment 
plays a role in the disease (120), DLBCL cell lines do not classify as well as 
patient samples. However, well-characterized cell lines can be used as models 
of the different subtypes of DLBCL in which to investigate the molecular 
mechanisms behind the disease. 
 
DLBCL pathogenesis 
An accumulation of genotoxic stress accompanies B cell development, 
including double stranded DNA breaks. The double-stranded DNA breaks that 
occur during VDJ recombination can result in recombinations that drive 
lymphomas (121, 122). During the GC reaction, B cells undergo additional 
double stranded DNA breaks during class switch recombination (123) and 
somatic hypermutation (124) that mainly affect the Ig locus. In DLBCLs 
trapped in the GC stage of differentiation, somatic hypermutation is an ongoing 
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process. These mutations can affect genes that are not usually targets of this 
process, which may introduce additional mutations to promote tumor survival 
(125, 126). For example, translocation of BCL6 occurs in about 25% of 
DLBCLs (127). Most of these translocations occur in the region that contains 
the first exon and the 5’ region of the first intron (128). BCL6 regulates an 
important group of oncogenes in normal B cells including BCL2, MYC, CCND1 
and BMI1 (129). Downregulation of BCL6 is required for exit from the GC and 
differentiation. In the presence of activating BCL6 translocations, GC B cells 
repression of these genes is disrupted (129), enabling tumor proliferation and 
survival. Accordingly, mice with constitutive expression of BCL6 in germinal 
center B-cells develop tumors that resemble human DLBCL (130, 131). 
Further, BCL6 is a therapeutic target in DLBCL (132). GCB DLBCLs may also 
exhibit BCL2 translocations (133), deletion of the tumor suppressor PTEN 
(134) or p53 mutations (135). 
 
ABC DLBCL exhibits genetic abnormalities unique to its subtype. Blimp-1, 
encoded by PRDM1, which represses BCL6, is frequently deleted in ABC 
DLBCL, blocking full differentiation into plasma cells (115, 128, 133, 136, 137). 
Other genetic aberrations include overexpression of BCL2 and amplification of 
the BCL2 locus (133). These lymphomas also exhibit deletions of the INK4A-
ARF locus, which encodes p16, an inhibitor of senescence, and p14ARF, an 
inhibitor of p53 activation (133, 138). The actions of chemotherapy are 
prevented in the absence of these tumor suppressors, which may explain why 
ABC DLBCLs have a poorer prognosis with conventional chemotherapy (133). 
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ABC DLBCL was initially identified and defined by a gene expression 
signature characteristic of normal B cells activated in vitro (119). Later studies 
showed that ABC DLBCL exhibits constitutive NF-κB activity that is required 
for lymphoma survival (139). In normal B cells, crosslinking of the BCR leads 
	  
Figure 1.6 B-cell differentiation and germinal center reaction. B cell 
precursors undergo V(D)J recombination to rearrange Ig heavy- and light-
chain genes until equipped with functional surface B cell receptor (BCR). 
Naïve B cells are activated when antigen binds BCR, then enter germinal 
centers (GCs) to proliferate into memory B cells. There, naïve B cells are 
replaced by proliferating B cells in the dark zone and undergo somatic 
hypermutation of the VH region to increase antibody affinity for antigen. Cells 
with mutations that increase the affinity of the receptor for antigen survive. 
Next cells undergo a process of class switching where the constant region of 
the heavy chain is replaced with that of another Ig gene. Interactions with T 
cells in the light zone can induce NF-κB activation. Finally, these cells 
differentiate into memory B cells or plasma cells and leave the GC. Modified 
from (97). 	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to phosphorylation of IκBα, leading to its ubiquitylation and degradation. This 
protein functions to sequester NF-κB subunits in the cytosol. When IκBα is 
degraded, NF-κB subunits translocate to the nucleus and activate an anti-
apoptotic transcriptional program. In ABC, but not GCB, DLBCL, interference 
with NF-κB signaling through retroviral transduction of a super-repressor form 
of IκBα or dominant negative forms of IκB kinase (IKK), the kinase that 
phosphorylates IκBα, killed lymphoma cells (139). Moreover, a target of NF-κB 
is the transcription factor IRF4 (140) that drives terminal B cell differentiation 
by transactivating Blimp-1 (141, 142). Together, IRF4 and Blimp-1 promote 
expression of XBP-1, a transcription factor that promotes the secretory 
phenotype (143-145). ABC DLBCLs express both IRF4 and XBP-1, but 
genetic inactivation of Blimp-1 blocks full plasmacytic differentiation of these 
cells (113, 128, 136, 137). 
 
BCR signaling 
Signaling through the BCR is required for B cell proliferation and survival. The 
BCR is a large transmembrane immunoglobulin receptor, most often IgM or 
IgD. The Igα/Igβ (CD79A/CD79B) heterodimer is associated with the BCR and 
acts as its signal transduction moiety. Ligand binding of the BCR causes 
aggregation of receptors, inducing phosphorylation of immunoreceptor 
tyrosine-based activation motifs (ITAMs) found on the cytoplasmic tails of 
CD79A/CD79B by src family kinases such as LYN, BLK and FYN. Spleen 
tyrosine kinase (SYK), a cytoplasmic tyrosine kinase is recruited to doubly 
phosphorylated ITAMs on CD79A/CD79B through its SH2 domain. Once 
docked, SYK is activated, and phosphorylates many downstream targets 
including the adaptor molecule BLNK. Concurrently, PI3-K is activated by 
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recruitment to the BCR coreceptor CD19, generating phosphatidylinositol 
3,4,5-triphosphate (PIP3), which activates the AKT/mTOR pathway. PIP3 binds 
to Bruton’s tyrosine kinase (BTK), recruiting it to the membrane, where it forms 
a complex with BLNK and phospholipase Cγ (PLCγ). Activation of these 
kinases by BCR aggregation results in the formation of the BCR signalosome 
at the cell membrane, comprised of the BCR, CD79A/CD79B heterodimer, src 
family kinases, SYK, BTK, BLNK and its associated signaling enzymes. The 
BCR signalosome mediates signal transduction from the receptor at the 
membrane to downstream signaling effectors. 
 
PLCγ cleaves phosphatidylinositol 4,5-bisphosphose (PIP2) into diacylglyercol 
(DAG) and the second messenger inositol trisphosphate (IP3), which activates 
both calcium release through the calcium-release-activated calcium (CRAC) 
channel and NFAT. DAG activates protein kinase Cβ (PKC-β) which 
phosphorylates latent CARD-11 causing its translocation to the cell membrane 
where it forms a multiprotein complex with MALT1, BCL10 and TRAF6. The 
ubiquitin ligase TRAF6 becomes autoubiquitinated and forms a complex with 
TAB2 and TAK1, the latter of which phosphorylates IKKβ, activating IKK to 
phosphorylate IκBα, leading to its degradation and activation of NF-κB 
signaling. The deubiquitinase A20 is a target gene of NF-κB that inhibits NF-
κB signaling by deubiquitinating IKK and TRAF6. 
 
Signals from the BCR signalosome are also transduced to extracellular signal-
related kinase (ERK) family proteins through Ras and to the MAPK family 
through Rac/cdc43. Activation of PLCγ causes increases in cellular calcium, 
resulting in activation of calcium-calmodulin kinase (CaMK) and NFAT. Many 
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other downstream effectors in this complex pathway (p38 MAPK, ERK1/2, 
CaMK) translocate to the nucleus to affect change in transcription of genes 
involved in cell survival, proliferation, growth and differentiation (Reviewed in 
146, 147). 
 
Chronic active BCR signaling in ABC DLBCL 
In an attempt to identify new therapeutic targets for ABC DLBCL, an “Achilles 
heel” RNA interference screen was used to identify genes necessary for tumor 
survival (148). Using this method, CARD11, BCL10 and MALT1, the three 
proteins of the CBM complex, were identified as necessary for ABC but not 
GCB DLBCL survival (148). As discussed, the transient activation of this 
complex leads to activation of NF-κB signaling in normal lymphocytes. The 
discovery of somatic mutations in CARD11 in ABC DLBCL explains the 
continuous requirement for this complex (149). Mutations in CARD11 are 
present in about 10% of ABC DLBCLs and can constitutively activate NF-κB 
when introduced to heterologous cells. Further, following BCR stimulation, 
these mutants can potentiate NF-κB signaling (149).  
 
In most ABC DLBCLs, CARD11 is not mutated, but these tumors still express 
high levels of NF-κB genes and wild-type CARD11 is required for ABC DLBCL 
cells. In these tumors, signaling molecules upstream of the CBM may activate 
CARD11 and NF-κB. An RNA interference screen identified that NF-κB 
signaling in ABC DLBCLs requires BTK, a tyrosine kinase required to connect 
BCR signaling to NF-κB signaling (150). The BCR itself activates BTK in these 
lymphomas, as knockdown of the BCR (immunoglobulin heavy or light chains), 
CD79A and CD79B is lethal to ABC DLBCLs with wildtype CARD 11 (150). 
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Total internal reflection fluorescent (TIRF) microscopy experiments 
demonstrated that the BCR of ABC DLBCLs exhibits prominent clustering with 
low diffusion in the cell membrane, as opposed to GCB DLBCLs that showed 
diffuse distribution of the BCR in the cell membrane (150). These clusters 
colocalized with phosphotyrosine suggesting that they represent active 
signaling (150). These clusters may form due to the presence of a yet 
unknown antigen or a defect in BCR membrane assembly. Genes in the BCR 
pathway were resequenced in order to provide genetic evidence of the role of 
BCR signaling in the pathogenesis of ABC DLBCL. These efforts revealed 
somatic mutations in CD79B in over one fifth of the ABC DLBCL patients 
examined as well as less frequent mutations in CD79A (150). These mutations 
occur in the ITAM motifs of CD79A and CD79B. As discussed, these motifs 
are the site of docking and activation for SYK as well as other kinases, and 
therefore critical for BCR signaling. Many of these mutations affect the first 
tyrosine of the CD79B ITAM motif. Other mutations affect other conserved 
ITAM residues or cause deletions in all or part of the ITAM motifs of CD79A 
and CD79B (150).  
 
The mutations in the CD79 subunits are not loss of function because they 
sustained survival in ABC DLBCL cells with knockdown of endogenous CD79 
isoforms. However, unlike CARD11 mutants, they do not spontaneously 
activate NF-κB when introduced into GCB DLBCL cells (150). Knock-in mice 
with loss or mutation of CD79A or CD79B ITAMs develop normal mature B 
cells that are, in fact, hyperresponsive to antigenic stimulation. B cells from 
these mice also exhibit higher levels of surface BCR expression because of 
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decreased receptor internalization (151-153). This phenomenon was also 
observed in ABC DLBCLs exhibiting or reconstituted with CD79 mutants of the 
first tyrosine residue of the ITAM. Mutations affecting the second tyrosine did 
not elevate surface BCR expression, nor have they been observed in patients, 
highlighting their functional nature. These mutations may have arisen in ABC 
DLBCLs to prevent signaling-induced receptor-internalization (150). 
 
The CD79 mutations also function to block negative regulation by the src 
family kinase LYN. Following BCR stimulation, LYN phosphorylates CD79 
ITAM residues as an early step in BCR signaling. However, LYN also 
negatively regulates this pathway (154, 155). LYN phosphorylates 
immunoreceptor tyrosine-based inhibitory motifs (ITIMs) on CD22 and the Fc 
γ-receptor, to which the phosphatase SHP1 is promoted, leading to ITAM 
dephosphorylation. LYN also phosphorylates SYK at a negative regulatory 
site, decreasing its activity. Lyn-deficient mice exhibit hyperactive BCR 
signaling that causes a severe autoimmune disease (156). ABC DLBCL cells 
reconstituted with mutant CD79B show less LYN kinase activity than with 
wildtype CD79B (150). 
 
This constitutive BCR activity in ABC DLBCLs was coined “chronic active BCR 
signaling” to distinguish it from the “tonic” BCR signaling that is a basal, 
ongoing requirement for mature B cell survival. Chronic active BCR signaling 
requires CARD11 and the CBM complex, whereas tonic BCR signaling does 
not (157). Also, chronic active BCR signaling is characterized by BCR 
clustering, which has not been observed in resting mature mouse B cells 
which require tonic BCR signaling for survival (158). Taken together, a model 
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of ABC DLBCL pathogenesis emerges in which CD79 mutations arise, 
allowing cells to avoid negative regulation of BCR signaling, activate NF-κB 
and escape cell death (Figure 1.6). 
 
Therapeutic targeting of BCR signaling in DLBCL 
Because it promotes cell growth, proliferation and survival, BCR signaling is a 
rational therapeutic target in DLBCL. As described, mutations in this pathway 
lead to its chronic activation, highlighting the therapeutic relevance of BCR 
signaling in ABC DLBCL. In fact, many components of the BCR pathway have 
been targeted in DLBCL, some of which have already been translated to 
patients (Figure 1.6). Overexpression of protein tyrosine phosphatase 
receptor-type truncated (PTPROt), a negative regulator of SYK, inhibits 
proliferation and induces apoptosis in DBLCL, identifying SYK as a target in 
DLBCL (159). Inhibition of SYK by the small molecular fostamatinib disodium 
(R406) blocks proliferation and induces apoptosis in DBLCL cell lines (160). 
This orally available compound has also shown significant clinical activity with 
good tolerance in DLBCL patients (161). Cerdulatinib (PRT2070), developed 
by Portola, is a dual SYK-JAK inhibitor that shows antitumor effect in a subset 
of DLBCL cell lines and is currently under clinical evaluation (162). PRT2607, 
a SYK-specific inhibitor, is also being developed in their pipeline. 
 
The constitutive activation of NF-κB in ABC DLBCL is an extremely attractive 
therapeutic target. NF-κB can be targeted through different approaches. IKK 
inhibition blocks phosphorylation of IκB, preventing release and nuclear 
translocation of NF-κB subunits. MLX105, a selective IKK inhibitor, potently 
kills ABC DLBCL cell lines (140). NEDD8-activating enzyme (NAE) regulates 
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the ubiquitination of phosphorylated IκB, resulting in its degradation and the 
release of NF-κB subunits to the nucleus. Inhibition of NAE by small molecules 
such as MLN4924 induces apoptosis in ABC DLBCL and shows strong tumor 
burden regression in DLBCL patient and xenograft models. Expectedly, the 
effects of MLN4924 are more potent in ABC DLBCL (163). Inhibition of PKCβ, 
the upstream activator of IKK, with sotrastaurin (STN) selectively inhibits the 
growth of CD79-mutant ABC DLBCL cell lines and xenograft models (164). 
MALT1 inhibitors comprise the newest class of compounds that target the 
constitutive NF-κB activity of ABC DLBCL. In 2012, two groups simultaneously 
reported selective inhibitors of MALT1 that induce cytotoxicity in ABC DLBCL 
cells, xenografts and patient models (165, 166). 
 
The PI3K/AKT/mTOR pathway is deregulated in many cancers including 
DLBCL (167). Small molecule inhibitors of this pathway have been heavily 
researched. Rapamycin (sirolimus), a macrolide antibiotic that targets mTOR, 
is an FDA approved oral immunosuppressant (168). Everolimus, an orally 
available rapamycin analog, has also been approved as a transplant 
immunosuppressant (169). These compounds have antitumor activity in 
DLBCL cell lines and patient samples, but their effect is mostly antiproliferative 
and only narrowly cytotoxic (167). Phase II clinical studies of everolimus in 
DLBCL have been moderately successful with an ORR of 35% (170). Inhibition 
of AKT is also a promising cancer therapy and can be targeted through 
several approaches. Perifosine, a lipid-based inhibitor that blocks the PIP3-
binding pleckstrin homology (PH) domain of AKT, preventing its translocation 
to the membrane, has shown antitumor activity both in vitro and in vivo. Small 
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molecule inhibitors of AKT, such as GSK690693, cause growth inhibition and 
apoptosis in lymphomas and leukemias (171).  
 
Many PI3K inhibitors have also been investigated in DLBCL. Pan-PI3K 
inhibitors, which block activity of all PI3K isoforms, such as buparlisib (NVP-
BKM120) have shown efficacy in both in vitro and in vivo models and is 
currently under clinical investigation in a phase II study of relapsed NHL 
including DLBCL (172). Inhibitors of specific isoforms of PI3K are also being 
investigated for DLBCL. For example, idelalisib (formerly CAL-101 or GS-
1101) is an oral, selective inhibitor of the p110δ isoform of PI3K that induces 
apoptosis in DLBCL cell lines and patient samples (173). A phase I clinical 
study of idelalisib showed efficacy in relapsed indolent lymphoma, but in 
another study of relapsed and refractory NHL patients, no response was 
observed in the DLBCL group (174). 
 
The MAPK pathway is another interesting therapeutic target in DLBCL. The 
oncogene MCT-1 is highly expressed in DLBCL patient specimens and 
regulated by ERK. Inhibition of ERK causes apoptosis in DLBCL xenograft 
models (175). Small molecule inhibitors or ERK and MEK have been 
developed and demonstrate excellent safety profiles and tumor suppressive 
activity in the clinic. Initial responses to these drugs, however, were not robust, 
with four partial patient responses observed and stable disease reported in 
22% of patient (176). Inhibition of MEK may be insufficient to cause 
cytotoxicity because of mutations in RAS and RAF, the upstream regulators of 
the MAPK pathway, may activate other kinases that maintain cell survival 
despite MEK inhibition. Despite these limitations, a small molecule inhibitor of 
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MEK, selumetinib (AZD6244), causes apoptosis in DLBCL cell lines, 
xenografts and patient samples and has entered the clinic (177). 
 
Perhaps the most advanced targeted therapy for DLBCL is BTK inhibition. An 
RNA interference screen showed that BTK knockdown was highly toxic for 
DLBCL cell lines, specifically ABC DLBCL, initially identifying BTK as a 
potential target (148). Ibrutinib (PCI-32765) is a potent, selective, irreversible, 
orally available small molecule inhibitor of BTK developed by Pharmacyclics, 
Inc. and Janssen Pharmaceuticals (178). Ibrutinib lacked significant activity 
	  
Figure 1.7 B cell receptor signaling in ABC-DLBCL. Schematic of B cell 
receptor signaling in ABC DLBCLs. Frequent mutations activate this pathway, 
elevating NF-κB signaling as well as other proliferation and survival pathways. 
As a result, inhibitors targeting many of these signaling molecules are in 
development. Adapted from (147). 	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against a panel of 19 BTK-related kinases and maintains over 1000-fold 
selectivity for B cells over T cells demonstrating its selectivity. Full BTK 
occupancy is achieved at 10 nM, and binding is irreversible as ibrutinib 
covalently binds to Cys481 of BTK. In vivo activity was shown in canine 
models of lymphomas (178). Ibrutinib also potently and selectively kills ABC 
DLBCL cell lines (150). Phase I clinical trials demonstrated that ibrutinib was 
well tolerated and had significant, durable activity in relapsed refractory B cell 
NHL and CLL, warranting further investigation in phase II trials of specific B 
cell malignancies (179, 180). In Phase II clinical trials, ibrutinib demonstrated a 
5.3% overall response rate (ORR) in GCB DLBCL and a 40% ORR in ABC 
DLBCL, with 8 out of 40 patients achieving complete response (CR) (181). 
Phase III studies evaluating ibrutinib as a frontline therapy for non-GCB 
DLBCL patients are ongoing (ClinicalTrials.gov identifier NCT01855750). 
 
Remarkably, ibrutinib achieved a 93% ORR in phase II studies of patients with 
relapsed refractory chronic lymphocytic leukemia (CLL) (182), and, in 
combination with rituximab, a monoclonal antibody against CD20, ibrutinib 
achieved a 95% ORR in high risk CLL patients (183). These promising studies 
led to FDA approval for CLL patients who have received at least one prior 
therapy and inspired numerous combination trials for other patients with B cell 
malignancies. A phase II clinical trial of ibrutinib in 111 patients with mantle 
cell lymphoma showed an ORR of 68% (21% CR) (184). These results led to 
FDA approval of ibrutinib for mantle cell lymphoma patients who have received 
at least one prior therapy. Other small molecule inhibitors of BTK are in 
various stages of development and have shown activity in laboratory and 
clinical settings (184-186). 
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Need for novel therapies 
Standard chemotherapy regimens for DLBCL such as the combination of 
cyclophosphamide, doxorubicin and vincristine, three chemotherapeutics, and 
prednisone, a steroid, (CHOP) cure about 40% of DLBCL patients, with 5-year 
overall survival rates for GCB and ABC patients of 60% and 30%, respectively 
(187). The addition of rituximab, a monoclonal antibody against CD20, to this 
treatment schedule (R-CHOP) increases survival of DLBCL patients by 10 to 
15% (188). However, 40% of DLBCL patients do not respond to R-CHOP. In 
the more aggressive ABC DLBCL subtype, the three year progression-free 
survival rate after R-CHOP is only 40% (147). Moreover, the side effects of 
this combination immunochemotherapy are not well tolerated, emphasizing the 
need for identifying novel targets and treatment regimens for this disease. 
 
Enormous advances have been made in targeted therapy for DLBCL, but as 
discussed, many of these agents do not achieve complete, durable responses. 
Single agent therapy is unlikely to be curative in DLBCL because of tumor cell 
heterogeneity, complex signaling pathways and feedback mechanisms and 
the emergence of resistance. Accordingly, many of the compounds for 
targeted therapy discussed above show increased efficacy when used in 
combination with chemotherapeutics or other targeted agents. The benefits of 
combination therapy include increasing therapeutic efficacy, minimizing the 
development of drug resistance, and decreasing toxicity. 
 
Consider ibrutinib, an FDA approved drug that has shown activity in ABC 
DLBCL. In Phase II clinical trials, as a single agent, ibrutinib exhibited 
moderate clinical activity, achieving 40% ORR in ABC DLBCL, with 8 out of 40 
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patients achieving complete response (181). When evaluated in combination 
with R-CHOP in a phase II study of DLBCL patients, the combination of 
ibrutinib and R-CHOP achieved 100% ORR with 60% CR (189). Moreover, 
mutations that confer resistance to ibrutinib have been reported (190, 191). 
The BTKC481S mutation observed in ibrutinib-treated CLL patients removed the 
cysteine required for ibrutinib action. Gain-of-function mutations in PLCγ2, a 
direct downstream target of BTK, have also been detected in CLL patients 
treated with ibrutinib. A large high-throughput combinatorial screen identified 
numerous drugs that synergize with ibrutinib to kill ABC DLBCL cells (192). 
Taken together, these studies demonstrate that even the most promising 
targeted therapies are unlikely to be curative as single agents and may be 
most effective when used in therapeutic combinations. However, the design of 
rational therapeutic combinations can be challenging given the massive 
numbers of drugs and the difficulty of defining the proteome that drives tumor 
cell survival independent of whether they are affected by somatic mutations. 
 
The role of Hsp90 in DLBCL  
The emerging role of Hsp90 inhibition in cancer therapy prompted our 
laboratory to investigate the role of PU-H71, a purine-scaffold Hsp90 inhibitor, 
in DLBCL (38). Cell viability assays showed that PU-H71 inhibits growth and 
induces apoptosis in a panel of DLBCL cell lines. This effect was more 
prominent in BCL6-dependent DLBCL cell lines with average GI50 1.39 μM 
(±1.00 μM) as compared to 71 μM (±41 μM) in BCL6 independent DLBCL cell 
lines, suggesting that PU-H71-induced apoptosis may occur through BCL6. 
Using PU-H71 chemical precipitation BCL6 was shown to interact physically 
with Hsp90 in DLBCL cells. More, exposure to PU-H71 resulted in time- and 
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dose-dependent degradation of BCL6 protein and mRNA, showing that it is a 
bona fide client of Hsp90. Immunohistochemical studies showed high 
expression of Hsp90 in 60 out of 70 DLBCL patient samples (85.7%). Of these 
samples, 87% were positive for BCL6, and 81% were positive for both Hsp90 
and BCL6, with a strong correlation of BCL6 and Hsp90 (r = 0.996, p < 
0.00001). Moreover, among 21 patient samples treated with PU-H71 (2.5 μM), 
19 cases showed greater than 25% loss of viability compared to vehicle 
treated controls. In vivo studies of PU-H71 showed potent suppression of 
tumor growth in three DLBCL xenograft models. Like other Hsp90 inhibitors, 
PU-H71 showed preferential uptake and retention in xenograft tumor tissue 
compared to normal tissues (38). Taken together, these studies demonstrate 
the effectiveness of targeting Hsp90 with PU-H71 in DLBCL. PU-H71 recently 
entered the clinical arena where it is well tolerated and accumulates in tumors 
at micromolar concentrations (193). 
 
In a later study from our laboratory (194), the gene signature induced by RI-
BPI, a peptidomimetic inhibitor of BCL6, was used to identify BCL6 targets and 
potential classes of drugs for therapeutic synergy in killing DLBCLs. The RI-
BPI-induced gene signature included genes associated with the actions of 
HDAC and Hsp90 inhibitors. Cerchietti et al (194) hypothesized that drugs with 
overlapping gene signatures with RI-BPI might enhance BCL6 inhibition 
thereby increasing downstream antilymphoma effects. Specifically, the lysine 
acetyltransferase p300 is directly repressed by BCL6, and exposure to RI-BPI 
induced expression of p300 and acetylation of its targets including Hsp90. 
Furthermore, combined inhibition of BCL6 with RI-BPI and Hsp90 with PU-H71 
synergized to kill a panel of DLBCL cell lines and also more potently inhibited 
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the growth of DLBCL xenograft models in vivo and human DLBCL patient 
samples ex vivo greater than either drug alone (194). These findings act as 
proof of principle that combined inhibition of Hsp90 and its client protein(s), in 
this case, BCL6, can achieve therapeutic synergy in DLBCL. 
 
Hypothesis 
Inhibition of teHsp90 with PU-H71 causes potent antilymphoma effects in 
DLBCL. The mechanism of this action occurs through inhibition of BCL6, one 
of the major oncogenes in DLBCL and a verified Hsp90 client. Given the 
complex signaling pathways involved in lymphomagenesis and DLBCL 
survival, and the ability of teHsp90 to chaperone multiple pathways that 
contribute to the malignant phenotype of other cancers, teHsp90 likely 
chaperones many other proteins and pathways in DLBCL. We therefore 
hypothesized that identification of the teHsp90 oncoproteome will reveal 
additional mechanisms of DLBCL survival. Because combined inhibition of 
teHsp90 and its client protein(s) can produce therapeutic synergy, we further 
predict that identifying oncogenic clients of teHsp90 in DLBCL will lead to 
rational combinatorial therapies anchored by PU-H71, geared toward more 
thorough suppression of key oncogenic pathways. 
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CHAPTER TWO 
teHsp90 pharmacoproteomics   reveals multiple interactions with BCR 
pathway proteins in DLBCL 
 
1. Introduction 
Hsp90 is a ubiquitously expressed molecular chaperone that maintains the 
conformational stability and function of numerous cellular proteins (1). These 
“client” proteins regulate many cellular processes including proliferation, 
growth and survival (1). Perhaps unsurprisingly, in order to maintain their 
malignant phenotype, tumor cells have hijacked this survival mechanism. In 
fact, tumor cells are enriched for a pool of Hsp90 (teHsp90) that preferentially 
binds oncoproteins required for tumor survival including chimeric fusion 
proteins, mutated molecules and effectors relied on by tumors through non-
oncogene addiction (1). teHsp90 exhibits a higher affinity for Hsp90 inhibitors 
than latent, housekeeping Hsp90, and can be depleted using Hsp90 inhibitors 
(30, 58). Upon Hsp90 inhibition, client proteins lose stability and are targeted 
for degradation by the proteasome, making teHsp90 inhibition an attractive 
therapeutic target in cancer (41). 
 
Work from our laboratory confirms that teHsp90 inhibition with the purine-
scaffold inhibitor PU-H71 is a viable therapeutic route in DLBCL. Experiments 
in DLBCL cells, xenografts and patient samples show that teHsp90 and BCL6 
form a complex whose activity is disrupted upon teHsp90 inhibition with PU-
H71, resulting in a potent antitumor effect (38). Further, we have shown that 
combined inhibition of teHsp90 and its client protein, BCL6, can synergistically 
kill DLBCL cells, xenografts and patient samples (194). The high affinity of PU-
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H71 to teHsp90 stress complexes has been harnessed as a proteomics 
capture approach to identify the cellular component of oncoproteins 
specifically contributing to the growth and survival of tumors (58, 74). For 
example, PU-H71 pulldowns performed in BCR-ABL driven leukemia cells 
capture BCR-ABL, but not the normal counterpart ABL protein. Both BCR-ABL 
and ABL are Hsp90 clients as shown by immunoprecipitation with an antibody 
to Hsp90, but only BCR-ABL is bound and stabilized by teHsp90 (150). 
 
Given the large number of proteins and pathways chaperoned by teHsp90 in 
other tumor types (1), we set out to identify the full teHsp90 oncoproteome in 
DLBCL. We hypothesized that identifying other teHsp90-chaperoned proteins 
and pathways critical to lymphomagenesis and DLBCL survival will further 
elucidate molecular mechanisms of DLBCL tumor biology. We further 
predicted that by focusing our analysis on druggable pathways, we could 
reveal translatable therapeutic combination treatments for DLBCL. Herein, we 
show that PU-H71 proteomics in DLBCL is a robust assay to identify signaling 
pathways critical to the tumor phenotype. We identified many BCR pathway 
proteins as components of teHsp90 complexes in DLBCL and show that 
several key kinases of this pathway are degraded with teHsp90 inhibition. 
 
2. Results 
2.1 Proteomic analysis of PU-H71 chemical precipitations in DLBCL cell 
lines 
Our lab has previously shown that PU-H71 can be used as a tool to chemically 
precipitate the teHsp90-proteome of cancer cells (58, 74). We predicted that 
using this method in DLBCL cells would identify client proteins necessary for 
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DLBCL survival and lead to rational combinatorial therapies anchored by PU-
H71. To identify the teHsp90 client proteins in DLBCL cell lines, we used 
agarose beads covalently attached to either an inert chemical or to PU-H71 to 
chemically precipitate teHsp90-client complexes in two GCB DLBCL cell lines, 
OCI-Ly1 and OCI-Ly7. 
 
	  
Figure 2.1 teHsp90 pharmacoproteomics in DLBCL cell lines (A) Lysates 
from OCI-Ly1 and OCI-Ly7 cells were subjected to chemical precipitation with 
PU-H71 or a control chemical followed by SDS PAGE and colloidal blue 
staining. The extracted proteins were examined by LC-MS/MS as shown in 
(B): Venn diagram is used to illustrate the numbers of overlapping and unique 
proteins identified by LC-MS/MS in each cell line.	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These complexes were resolved by polyacrylamide gel electrophoresis 
followed by Coomassie blue staining of the gel in order to visualize the 
proteins. We observed that lysates incubated with control beads showed 
almost no detectable protein in the gel, especially when compared with the 
lanes of lysate incubated with PU-H71 beads, which showed a variety of 
proteins at all sizes (Figure 2.1 A). Bands were cut from the gel under sterile 
conditions and analyzed by liquid chromatography followed by tandem mass 
spectrometry (LC-MS/MS). After subtracting common contaminants and the 
agarose proteome (195), we identified 602 and 684 teHsp90 client proteins in 
OCI-Ly1 and OCI-Ly7, respectively (Figure 2.1 B, Table 2.1). Of the identified 
proteins, 52% were common to both cell lines, demonstrating the consistency 
of this assay across cell lines. 
 
2.2 Visualization of teHsp90 client pathways 
To identify the signaling networks most highly represented among the teHsp90 
complexes in DLBCL, we analyzed the union of OCI-Ly1 and OCI-Ly7 client 
proteins using the Search Tool for the Retrieval of Interaction Genes/Proteins 
(STRING) with a confidence of 0.99 (196). Among the expected clusters of 
proteins chaperoned by teHsp90 stress complexes we identified components 
of the proteasome and ribosomal proteins. However, the teHsp90 complexes 
in our proteomics dataset were also highly enriched for proteins that form part 
of the B cell receptor (BCR) signaling pathway (Figure 2.2A). An orthogonal 
pathway analysis approach using Ingenuity Pathway Analysis (IPA) also 
identified the BCR pathway as highly represented in the teHsp90 DLBCL 
interactome (p=0.01) (Table 2.1).  
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Table 2.1 PU-H71 proteomics reveals teHsp90-chaperoned pathways. 
The union of proteins identified in OCI-Ly1 and OCI-Ly7 PU-H71 proteomics 
assays were subjected to Ingenuity Pathway Analysis. Significantly 
represented pathways are listed here. BCR pathway is highlighted in orange. 
Ingenuity Canonical Pathways 
 -log(p-
value) Ingenuity Canonical Pathways 
 -log(p-
value) 
EIF2 Signaling 28.70 Ephrin B Signaling 4.80 
Protein Ubiquitination Pathway 25.80 Huntington’s Disease Signaling 4.79 
Regulation of eIF4 and p70S6K 
Signaling 17.20 B Cell Development 4.67 
tRNA Charging 13.20 Integrin Signaling 4.66 
mTOR Signaling 11.80 CD28 Signaling in T Helper Cells 4.65 
p70S6K Signaling 11.20 B Cell Receptor Signaling 4.49 
Actin Cytoskeleton Signaling 10.30 
DNA Double-Strand Break Repair 
by NHEJ 4.44 
Purine Nucleotides De Novo 
Biosynthesis II 7.35 RhoA Signaling 4.35 
PI3K/AKT Signaling 7.27 
Methionine Degradation I (to 
Homocysteine) 4.24 
Systemic Lupus Erythematosus 
Signaling 6.58 
CTLA4 Signaling in Cytotoxic T 
Lymphocytes 4.23 
RAN Signaling 6.15 
PKCθ Signaling in T 
Lymphocytes 4.10 
14-3-3-mediated Signaling 6.01 Protein Kinase A Signaling 4.06 
Cell Cycle: G2/M DNA Damage 
Checkpoint Regulation 6.00 FAK Signaling 3.98 
Breast Cancer Regulation by 
Stathmin1 5.84 fMLP Signaling in Neutrophils 3.95 
VEGF Signaling 5.82 PRPP Biosynthesis I 3.88 
Role of NFAT in Regulation of the 
Immune Response 5.77 
5-aminoimidazole Ribonucleotide 
Biosynthesis I 3.88 
Signaling by Rho Family GTPases 5.71 G Beta Gamma Signaling 3.87 
ILK Signaling 5.60 
Virus Entry via Endocytic 
Pathways 3.81 
Fcγ Receptor-mediated 
Phagocytosis in Macrophages and 
Monocytes 5.40 RhoGDI Signaling 3.74 
Glycolysis I 5.20 ERK/MAPK Signaling 3.69 
Clathrin-mediated Endocytosis 
Signaling 5.10 PI3K Signaling in B Lymphocytes 3.57 
Tight Junction Signaling 5.00 Calcium Signaling 3.54 
Germ Cell-Sertoli Cell Junction 
Signaling 4.90 
Cell Cycle Control of 
Chromosomal Replication 3.50 
Gap Junction Signaling 4.90 Phospholipase C Signaling 3.50 
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Among the components of the BCR pathway present within teHsp90 stress 
complexes were the B-cell receptor itself (Igμ), as well as many canonical 
components including CD79A, CD79B, SYK, BTK, SHP1, PLCγ2, CD45, LYN, 
VAV, RAC, PI3K, mTOR, CSK, MEKK, JNK1/2 and several NF-κB 
components (Figure 2.2B).  
 
2.3 teHsp90 complexes maintain protein expression of core components 
of the BCR pathway in GCB and ABC DLBCL cells 
In order to validate the teHsp90 pharmacoproteomics assays, we next 
performed PU-H71 chemical precipitations in OCI-Ly1 and OCI-Ly7 cells 
followed by immunoblot for many of the BCR pathway proteins identified by 
LC-MS/MS. All of these protein interactions were confirmed by chemical 
precipitation/immunoblot, demonstrating the robustness and accuracy of the 
pharmacoproteomics assay. Additionally, B-cell linker protein (BLNK), a 
scaffolding protein in the BCR pathway, which was not present in the LC-
MS/MS assays failed to be captured as a component of teHsp90 complexes in 
these validation studies, further confirming the accuracy of the proteomic 
analysis (Figure 2.3A).  
 
Classical Hsp90-regulated client proteins depend on Hsp90 function for their 
stability. To determine if the stability of the BCR proteins identified by LC-
MS/MS was dependent on teHsp90 complexes, we exposed OCI-Ly1 and 
OCI-Ly7 cells to increasing doses of PU-H71 for 24 hours and analyzed the 
abundance of the proximal enzymes of the BCR pathway by immunoblot. The 
proteins LYN, SYK, BTK and PLCγ2 were depleted in a dose-dependent 
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manner upon exposure to PU-H71, showng their dependency on teHsp90 
complexes to maintain their expression (Figure 2.3B).  
 
The more aggressive, therapy-resistant activated B cell like (ABC) subtype of 
DLBCL features chronic activation of BCR signaling, often due to the presence 
of somatic mutations of proteins in this pathway (150). As such, ABC DLBCLs 
are sensitive to targeted therapies that disrupt BCR signaling. We wondered 
whether the BCR proteins identified by proteomics were also associated with 
 
Figure 2.2 Pathways identified by PU-H71 proteomics in DLBCL (A) 
STRING representation of the union of proteins identified in OCI-Ly1 and OCI-
Ly7 PU-H71 chemical precipitations at 0.99 confidence. (B) A representation 
of the BCR pathway is shown. Proteins with blue color were identified as 
components of the teHsp90 interactome by LC-MS/MS. 	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Figure 2.3 BCR pathway proteins interact with and require teHsp90 to 
maintain their expression. (A) Lysates from OCI-Ly1 and OCI-Ly7 were 
subjected to chemical precipitation with PU-H71 (PU) or control chemical (CO) 
beads followed by immunoblotting for the indicated BCR pathway proteins. 
Hsp90 is used as a positive control. (B) OCI-Ly1 and OCI-Ly7 cells were 
exposed to vehicle or increasing doses of PU-H71 for 24 hours as indicated. 
Lysates were subjected to immunoblotting with the indicated antibodies. β-
actin was used as a loading control. The relative abundance of each protein 
relative to β-actin was quantified by densitometry for each timepoint 
represented in the line graph below as average ± SEM (n=3). 
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teHsp90 complexes in ABC DLBCL cell lines. If so, PU-H71 might serve as a 
candidate therapeutic agent for ABC DLBCLs. To test this, we performed PU-
H71 chemical precipitations followed by immunoblot for BCR pathway proteins 
in two ABC DLBCL cell lines, HBL-1 and TMD8. We observed that the BCR 
proteins identified by LC-MS/MS in GCB DLBCL cell lines were also bound to 
teHsp90 complexes in these ABC DLBCL cells (Figure 2.4A). Moreover, the 
proteins SYK, BTK and PLCγ2 demonstrated dose-dependent expression 
reduction upon exposure to PU-H71 (Figure 2.4B). LYN showed the same 
trend, despite showing robust interactions with teHsp90-PU-H71 complexes in 
only one cell line tested. In HBL-1 and TMD8, CD79B was more abundant in 
teHsp90 complexes than in the GCB DLBCL cell lines tested, which may be 
because it is mutated and constitutively active in these cell lines (150).  
 
3. Discussion 
In this work, we identify the PU-H71 teHsp90 oncoproteome of DLBCL. The 
highly stable binding of PU-H71 to teHsp90 enables the enrichment of the 
teHsp90 proteome from cells using PU-H71 pulldowns (58, 74). This method 
can be used to specifically capture a unique functional class of Hsp90 
complexes that exhibits greater association with biochemical effects 
specifically required by tumor cells to maintain their growth and survival (58, 
74). 
 
Some of the pathways enriched in teHsp90 complexes identified in our 
approach are well-characterized clients of Hsp90, including the proteasome, 
chaperonins, replication machinery and translation machinery. For example, 
Hsp90 client proteins identified by a yeast two-hybrid screen sorted
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Figure 2.4 BCR pathway proteins interact with and require teHsp90 to 
maintain their expression in ABC DLBCLs. (A) Lysates from HBL-1 or 
TMD8 cells were subjected to chemical precipitation with PU-H71 (PU) or inert 
chemical (CO) beads followed by immunoblotting for the indicated BCR 
pathway proteins. Hsp90 is used as a positive control. (B) HBL-1 and TMD8 
cells were exposed to vehicle or increasing doses of PU-H71 for 24 hours as 
indicated. Lysates were subjected to immunoblotting with the indicated 
antibodies. β-actin was used as a loading control. The relative abundance of 
each protein relative to β-actin was quantified by densitometry for each 
timepoint and is shown in the line graph below as average ± SEM (n=3).	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into functional categories showed many interacting proteins to be involved in 
cell cycle and DNA processing, protein fate, and transcription (197). These 
experiments were performed in yeast, suggesting that the role of Hsp90 in 
regulating these processes required for cell survival is evolutionarily 
conserved. 
 
In another study using HEK293T cells, proteins involved in transcription, 
ubiquitination, protein folding and the unfolded protein response were 
identified as Hsp90 clients, and that most ATP-dependent Hsp90 interactions 
were disrupted with GM treatment (198). Other approaches using immobilized 
Hsp90 as bait also revealed transcription and translation proteins as Hsp90 
clients (199). In other efforts to map the global principles of Hsp90 
interactions, using many different approaches, some complexes and pathways 
identified with our approach have been shown to be clients of Hsp90, placing 
our approach firmly within the field of Hsp90 affinity capture and confirming the 
accuracy of our technique. 
 
The signaling pathways identified in our PU-H71 proteomics assays are more 
intriguing from a functional and therapeutic standpoint. Other proteomic 
methods have been utilized to explain the basis of Hsp90-kinase recognition 
(200) and to show that Hsp90 inhibition preferentially targets kinases and the 
DNA damage response (201), another pathway identified in our proteomics 
assay. In fact, the highest scoring signaling networks enriched by PU-H71 
pulldown proteomics in BCR-ABL positive CML were those known to be used 
by BCR-ABL to propagate aberrant signaling in CML. These pathways include 
the PI3K-AKT-mTOR, NF-κB, Raf-MAPK, STAT, and focal adhesion. These 
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findings led to the discovery of a new STAT activation mechanism critical to 
CML survival (58). We used PU-H71 proteomics in a collaboration project to 
investigate KSHV+ PELs. In these cells, the PU-H71 pulldowns enriched for 
proteins of the following pathways: NF-κB activation by viruses, apoptosis, 
autophagy, PI3K/AKT-mTOR, interleukin 6, angiogenesis, and vascular 
endothelial growth factor signaling (74). Representative proteins of these 
pathways were validated using PU-H71 pulldown followed by immunoblot in 
four KSHV+ PEL cell lines (74). Our proteomics assays in DLBCL revealed 
some of the same pathways that are well known to be important effectors of 
tumor cell signaling, including PI3K/AKT/mTOR signaling and ERK/MAPK 
signaling. 
 
However, each of these studies also identified pathways uniquely required for 
survival by the specific type of cancer investigated. Similarly, our PU-H71 
proteomics identified a signaling pathway known to be critical to DLBCL 
survival – the BCR pathway. Although expected, this result further 
demonstrates that PU-H71 affinity capture selects for the pool of teHsp90 that 
chaperones those proteins and pathways required for maintaining a specific 
tumor phenotype. 
 
It is important to note that the initial proteomic assays were performed in GCB 
DLBCL cell lines as a hypothesis-generating experiment. The BCR pathway is 
known to be chronically active and therapeutically targetable in the ABC 
DLBCL subtype (150). However, GCB DLBCLs exhibit tonic BCR activity and 
are sensitive to inhibition of certain kinases in the pathway (160). Though 
teHsp90 preferentially chaperones oncogenic, often mutated client proteins, 
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the BCR pathway does not harbor mutations in the GCB DLBCL subtype, but 
is still chaperoned by teHsp90. Hence it is possible that Hsp90 is required for 
chaperoning of this pathway in both subtypes, albeit for different functions. 
Notably, CD79B, which is mutated in the HBL-1 and TMD8 ABC DLBCL cell 
lines (150), appears to be more abundantly present in teHsp90 complexes 
identified by PU-H71 chemical precipitation than in the GCB DLBCL cells. 
 
4. Materials and methods 
Cell lines and reagents The DLBCL cell lines OCI-Ly1 and OCI-Ly7 were 
grown in Iscove’s Modified Dulbecco’s Medium (IMDM) containing 10% FBS 
and supplemented with penicillin and streptomycin. The DLBCL cell lines HBL-
1 and TMD8 were grown in medium containing 90% RPMI and 10% FBS, 
supplemented with L-glutamine, HEPES and penicillin and streptomycin. PU-
H71 was synthesized as previously described (58). The following antibodies 
were used: CD79A clone HM47, Santa Cruz Biotechnology; CD79B clone SN8 
and FL-229, Santa Cruz Biotechnology; LYN clone 44, Santa Cruz 
Biotechnology; SYK clone 4D10, Santa Cruz Biotechnology; BTK clone D3H5, 
Cell Signaling Technology; PLCγ2 clone Q-20, Santa Cruz Biotechnology; 
BLNK clone 2B11, Santa Cruz Biotechnology; Hsp90 catalog number 
ab13495, Abcam; β-actin clone AC-15, Sigma Aldrich. 
 
Cell treatments Unless otherwise noted, cells were counted and assayed for 
viability using Trypan blue dye exclusion. Cells were centrifuged at 1500 rpm 
for 5 minutes at room temperature and resuspended in fresh media at a 
concentration of 2 x 106 cells/mL. 
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PU-H71 chemical precipitation PU-H71 and control (Hsp90 inactive 
chemical (2-methoxyethylamine)) beads were synthesized as previously 
reported (58). Before use, PU-H71 and control beads were washed three 
times in Felts buffers (20 mM HEPES, 50 mM KCl, 5 mM MgCL2, 0.01% (w/v) 
NP-40, freshly prepared 20 mM Na2MoO4 and protease inhibitors (Roche, 
Indianapolis, IN)). For cell lysis, 40 million (immunoblot) or 100 million 
(proteomics) cells were spun down at 1500 rpm for 5 minutes, washed in 1X 
phosphate buffered saline (PBS), resuspended in 1 mL of Felts buffer and 
incubated on ice for 30 minutes. Pellets were vortexed for 15 seconds on high 
and centrifuged at 14,000 rpm for 15 minutes at 4°C. Supernatants were 
collected and precleared by incubating with 100 μL of washed control beads. 
For immunoblot, lysates were precleared for one hour rocking at 4°C. For 
proteomics, lysates were precleared for 8 hours rocking at 4°C, and then again 
with fresh beads overnight rocking at 4°C. Following preclearing, lysates were 
split, saving 10% of each pulldown to be used as input, and half of the 
remaining sample was incubated with 100 μL of either control of PU-H71 
beads at 4°C overnight. Samples with PU-H71 beads were incubated in amber 
tubes to prevent PU-H71 light-sensitive degradation. Following incubation, 
beads conjugates were washed 3 times with Felts buffer by adding 1 mL fresh, 
cold Felts buffer, vortexing for 10 seconds, and spinning at 10,000 rpm for 1 
minute. Precipitates were resolved by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) following standard immunoblotting 
procedure. For proteomics, gels were stained with colloidal blue, cut into 
bands under sterile conditions, frozen on dry ice and sent for mass 
spectrometry analysis. 
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Mass spectrometry 
In-gel trypsin-mediated digestion was carried out using standard procedures. 
Tryptic peptides were resolved on a nano-capillary reverse phase column and 
directly infused into a linear ion-trap mass spectrometer (LTQ Orbitrap XL, 
Thermo Fisher Scientific). The mass spectrometer was set to collect on survey 
scan (MS1), followed by MS/MS spectra on the 9 most intense ions observed 
in MS1 scan. Proteins were identified by searching the tandem mass spectra 
against human protein database using X!Tandem/TransProteomic Pipeline 
software suite. All proteins identified with a probability of >0.9 were retained for 
further analysis. Common contaminants and the agarose protome (195) were 
subtracted before further analysis. 
 
Cell lysis for immunoblot 
Cells were harvested, spun down at 1500 rpm for 5 minutes at room 
temperature. Pellets were washed in PBS, and then centrifuged again. After 
PBS aspiration, pellets were resuspended in lysis buffer (10 mM HEPES-KOH 
pH 7.9, 1.5 mM MgCl2, 10 mM KCl, freshly prepared NaMoO4, 1% Triton-X, 
0.5 mM phenylmethylsulfonyl fluoride (PMSF), and protease and phosphatase 
inhibitors) by flicking the tube. Cells were incubated in lysis buffer on ice for 15 
minutes, vortexed on high for 5 seconds, centrifuged at 14,000 rpm for 10 
minutes at 4°C and prepared for downstream assays. 
 
Statistical analysis 
Two-tailed unpaired t test was used unless otherwise stated. All statistical 
analyses were carried out using Prism software (GraphPad). 
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CHAPTER THREE 
Inhibition of teHsp90 induces broad attenutation of BCR signaling at 
multiple nodes 
 
1. Introduction 
Clients of teHsp90 depend on its chaperoning activity to maintain not only their 
stability, but also their function. As such, teHsp90 has been shown to mediate 
novel functions in protein physiology, independent of its effects on protein 
folding and stability (3,5). For example, in B-CLL, teHsp90 maintains LYN in 
an active conformation (10). In CML cells, teHsp90 regulates the conformation 
of STAT5 in order to sustain elevated levels of active pSTAT5 species in the 
cell (5). Further, in DLBCL, teHsp90 was shown to maintain the BCL6 
transcriptional repressor in a DNA-bound active conformation (3). We 
therefore hypothesized that teHsp90 is required for the activity of the proximal 
enzymes of the BCR pathway independent of its function in maintaining the 
expression of these proteins.  We further predict that due to the extensive 
interactions between teHsp90 and the BCR pathway identified by mass 
spectrometry, teHsp90 plays a broad role in regulating BCR pathway activity. 
 
2. Results 
2.1 teHsp90 is required for activation of BCR signaling proteins 
Because teHsp90 is known to chaperone not only the stability but also the 
function of its client proteins, we wondered if teHsp90 function was required for 
the activity of the proximal enzymes of the BCR pathway, independent of its 
function in maintaining expression of these proteins. To test this, we treated 
three ABC DLBCL cell lines with PU-H71 at time points up to four hours, which 
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is before reduction of protein abundance is observed. Immunoblots of these 
lysates were performed for total and activating phosphorylated forms of SYK, 
BTK and PLCγ2. In three ABC DLBCL cell lines, HBL-1, TMD8 and OCI-Ly10, 
phospho-SYK Y352, phospho-BTK Y223, and phospho-PLCγ2 Y759 
decreased in a time-dependent manner upon exposure to PU-H71, 
independent of total protein levels (Figure 3.1). 
 
2.2 teHsp90 is required for BCR signalosome complex function 
2.2.1 Membrane localization of Hsp90 in DLBCL cells 
teHsp90 regulates the activity and dynamics of signaling complexes required 
for cancer cell survival (58, 74). PU-H71 disrupts the dynamics of stress 
	  
Figure 3.1 teHsp90 is required for basal BCR signaling in ABC DLBCL. 
HBL-1, TMD8 and OCI-Ly10 cells were exposed to vehicle or PU-H71 for 
increasing times as indicated. Lysates were subjected to imunoblotting with 
the indicated antibodies. β-actin was used as a loading control. The relative 
abundance of each phosphorylated protein relative to each total protein was 
and each total protein relative to β-actin was quantified by densitometry for 
each timepoint and is shown in the line graph (total).  	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complexes by maintaining teHsp90 in the ATP-bound configuration attached to 
its partner proteins (58). Given the interaction of teHSp90 with CD79A and 
CD79B, the BCR-associated transmembrane protein heterodimer that serves 
as the its signal transduction moiety, and the BCR itself, we wondered if 
teHsp90 chaperones the BCR at the cell membrane. To address this question, 
we first wanted to determine if Hsp90 is localized at the cell membrane in 
DLBCL cells. To test this, we used a cell fractionation method to purify 
membrane and cytosolic fractions of OCI-Ly7 and HBL-1 cells. Although not 
abundant, we detected expression of Hsp90 in the membrane fraction of both 
of these cell lines (Figure 3.2A) CD79A, which is predominantly localized in 
the membrane, was used as a control and showed the opposite localization 
pattern in these cells. 
 
As an orthogonal assay to demonstrate membrane localization of Hsp90, we 
used total internal fluorescence microscopy (TIRFM), which is used for 
imaging of membrane biology. In these assays, HBL-1 or TMD8 cells were 
adhered to coverslips, fixed, and then stained with antibodies to Hsp90 or SYK 
followed by secondary antibodies conjugated to fluorophores and a 
fluorophore-conjugated antibody to IgM. TIRFM, which only penetrates 200 nm 
into sample allowing for imaging of membrane biology, was used to image 
these cells and revealed clear localization of Hsp90 at the membrane in both 
HBL-1 and TMD8 cells (Figure 3.2B). Moreover, these images depicted 
clustering of the B cell receptor (IgM) in TMD8 cells, as has been described 
(150). Our images also show considerable co-localization of Hsp90 with SYK 
at the membrane (Figure 3.2B). Taken together, this data suggests that Hsp90 
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is localized to the cell membrane in DLBCL cell lines, suggesting that its 
chaperone function may also take place in the membrane. 
 
 
 
	  
Figure 3.2 Membrane localization of Hsp90. (A) HBL-1 and OCI-Ly7 cells 
were subjected to cellular fractionation. Membrane (M) and cytoplasmic (C) 
fractions were immunoblotted with the indicated antibodies. (B) TMD8 cells 
were stained for IgM and Hsp90 with fluorescent conjugated antibodies and 
imaged using TIRFM (upper row). HBL-1 cells were stained for SYK and 
Hsp90 with fluorescent conjugated antibodies and imaged using TIRFM 
(lower row). 	  
	   59	  
2.2.2 PU-H71 disrupts BCR-lipid raft association 
Following ligation and aggregation of the BCR, the clustering and proximity of 
BCRs in lipid rafts causes amplification of BCR signaling (202). Because 
components of the BCR were identified in teHsp90 proteomics assays and 
exposure to PU-H71 diminished BCR signaling activity, we wondered if the 
PU-H71-induced loss of proximal BCR enzyme activity was due to decreased 
BCR-lipid raft association. To test this, we measured colocalization of the BCR 
with lipid rafts in DLBCL cells exposed to PU-H71 for 4 hours (the time when 
maximal decrease of SYK, BTK, and PLCγ2 activity independent of total 
protein degradation was observed). To visualize the BCR, we used an 
antibody to IgM conjugated to a fluorophore. To visualize lipid rafts, we stained 
cells with filipin, a small molecule that forms a fluorescent complex with 
cholesterol (203-205). Using confocal microscopy and the Costes’ automatic 
thesholding method (206), we measured BCR-lipid raft colocalization in two 
ABC DLBCL cell lines in the presence of PU-H71 or vehicle. We observed a 
significant decrease in BCR-lipid raft colocalization in the presence of PU-H71 
(Figure 3.3).  
 
2.2.3 teHsp90 is required for dynamic assembly of the BCR signalosome 
complex 
Given the observed attenuation of SYK, BTK and PLCγ2 phosphorylation upon 
PU-H71 exposure, we wondered whether teHsp90 was required for dynamic 
assembly of the BCR signalosome complex and if PU-H71 would disrupt this 
effect. To address this question, we interrogated the BCR signalosome using 
TIRFM in cells exposed to PU-H71 for four hours, the timepoint at which 
maximal suppression BCR signaling by PU-H71 independent of total protein 
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degradation was observed. For these assays, we used TIRFM to visualize 
IgM-SYK association in vehicle or PU-H71 treated cells. To visualize the BCR 
we used an antibody to IgM conjugated to a fluorophore. To visualize SYK we 
used a primary antibody against human SYK and then a secondary antibody 
conjugated to a different fluorophore. We imaged control and treated cells 
using TIRFM and quantified IgM:SYK colocalization by counting IgM clusters 
that were also SYK positive. We initially expected to see high basal IgM:SYK 
association that would be disrupted in the presence of PU-H71, but instead 
observed 36% of IgM clusters colocalized with SYK in vehicle treated cells 
compared to 53% of IgM clusters colocalized with SYK in PU-H71 treated cells 
(p=0.03) (Figure 3.4).  
 
As an orthogonal method to test this hypothesis, we used a biochemical 
approach: endogenous co-immnoprecipitation assays in cells treated with 
	  
Figure 3.3 PU-H71 disrupts BCR-lipid raft association. IgM and lipid rafts 
of HBL-1 and OCI-Ly10 cells exposed to vehicle or PU-H71 (1 µM, 4h) were 
visualized by confocal microscopy (60X). Colocalization was quantified with 
the Costes method for at least 10 high power fields in at least two independent 
experiments. Unpaired t-test. 	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vehicle or PU-H71 at the short time points where loss of kinase 
phosphorylation was observed independent of effects on total protein 
abundance. Due to the chronic activation of the BCR pathway in these cell 
lines (150), we expected to observe high basal levels of CD79A interaction 
with SYK and BTK that would be disrupted upon exposure to PU-H71. 
However, we observed very low basal interaction of CD79A with SYK and no 
interaction of CD79A with BTK at basal levels (Figure 3.5) Further, we 
observed a time-dependent increase in the amount of SYK and BTK co-
	  
Figure 3.4 PU-H71 induces IgM cluster association with SYK. HBL-1 cells 
exposed to vehicle or PU-H71 (1 µM, 4h) were stained with fluorescent 
antibodies to IgM and SYK and visualized by TIRFM. Colocalization was 
quantified by counting IgM clusters that were SYK positive (white arrows, 
SYK-negative clusters represented with black arrow). Unpaired t-test. 	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immunoprecipitated with CD79A in cells exposed to PU-H71 (Figure 3.5). The 
presence of Hsp90 within the BCR signalosome complex was verified by 
probing the immunoblots of these assays with an antibody to Hsp90 (Figure 
3.5). These immunoblots were also probed with an antibody to CD79A as a 
control for immunopreceipitation efficiency and observed no change.  
This PU-H71-induced accumulation of SYK and BTK on CD79A occurs at 
times of PU-H71 exposure when SYK and BTK exhibit reduced activity and 
decreased association of the BCR with lipid rafts is observed, suggesting that 
	  
Figure 3.5 PU-H71 induces freezing of the BCR signalosome complex. 
Lysates of HBL-1 or TMD8 cells exposed to vehicle or PU-H71 (1µM) for the 
times indicated were immunoprecipitated with antibodies to CD79A or IgG and 
immunoblotted with the indicated antibodies. Input is 2% of each IP. 
Densitometry quantified using ImageJ relative to 0h is noted. 	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this buildup of kinases on the BCR represents a loss of dynamic BCR complex 
function, likely due to inhibition of the Hsp90 chaperone cycle. Collectively 
these data suggest that teHsp90 contributes to BCR functionality by enabling 
lipid raft localization and dynamic interactions with its downstream mediators. 
 
During signaling, BCR signalosome components must dynamically recycle 
configurations in order to provide ongoing BCR signaling required for cell 
survival. BCR surface expression is elevated in ABC-DLBCLs, which result 
from the CD79 mutations present in these cells to maintain chronic active 
signaling (150). We wondered if PU-H71-induced freezing of the BCR 
signalosome was associated with increased internalization of the receptor. To 
test this hypothesis, we performed a flow cytometry based BCR internalization 
assay in cells treated with vehicle or PU-H71. We observed mild, but 
significant increases in BCR internalization in cells treated with PU-H71 
(Figure 3.6).  
 
2.3 Signaling induced by BCR stimulation requires teHsp90 function 
2.3.1 Antigen-induced BCR signalosome activation 
To further demonstrate that accumulation of SYK and BTK with the BCR is 
associated with a loss of BCR signalosome complex function, we pretreated 
cells with 1 µM PU-H71 for 1 hour before stimulating the BCR with IgM + IgG 
(10 µg/mL), and then measured the activity of SYK and BTK by phospho-
immunoblot in HBL-1 and TMD8 ABC DLBCL cells. We observed that PU-H71 
inhibited BCR-stimulated activation of SYK by 33% in TMD8 cells, although 
there was only a minimal reduction in HBL-1 (Figure 3.7A). PU-H71 more 
powerfully inhibited BCR-stimulated activation of BTK by 50% and 62% in 
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HBL-1 and TMD8 cells, respectively (Figure 3.7A). We used intracellular 
phosphoflow cytometry as an orthogonal assay to further examine the BCR 
signaling pathway. In HBL-1 cells we observed a 20-30% decrease in SYK, 
BTK and PLCγ2 activation following BCR stimulation in cells pretreated with 
PU-H71 (p≤0.0001, Figure 3.7B). In OCI-Ly10 cells, we observed a 15-25% 
reduction in antigen-induced kinase activation in cell pretreated with PU-H71 
(p≤0.01, Figure 3.7B). We also observed this effect in GCB DLBCL cells. In 
OCI-Ly1 cells pretreated with PU-H71, we observed a 15-25% decrease in 
BCR-stimulated kinase activation (Figure 3.7B). 
2.3.2 Calcium mobilization 
Inhibition of teHsp90 with PU-H71 disrupts dynamic recycling of the BCR 
signalosome and prevents BCR-stimulated activation of SYK, BTK and PLCγ2, 
the proximal enzymes of the BCR pathway contained in the signalosome. We 
wondered if BCR signaling downstream of the membrane is teHsp90-
dependent. To test this, we used a fluorescent calcium indicator (Fluo-4 
	  
Figure 3.6 PU-H71 induces BCR internalization. HBL-1 and TMD8 cells 
treated with vehicle or PU-H71 (1 µM, 2h) were incubated with IgM (10 µg/mL) 
on ice before incubation at 37°C for the times indicated, then fixed and stained 
with a fluorescent-conjugated secondary antibody. BCR surface expression 
was quantified using flow cytometry (*p<0.05, n=3). 	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Figure 3.7 BCR-stimulated activation of proximal BCR signaling requires 
teHsp90 function. (A) Lysates of HBL-1 and TMD8 cells exposed to vehicle or 
PU-H71 (1 µM) before BCR stimulation (IgM+IgG 10 µg/mL) were subjected to 
immunoblotting. (B) HBL-1, OCI-Ly10 and OCI-Ly1 cells treated with vehicle or 
PU-H71 (1 µM, 1h) before BCR stimulation (IgM+IgG 10 µg/mL, 15min) were 
fixed, permeabilized and stained with phospho-antibodies or isotype controls. 
Phospho-proteins were quantified using flow cytometry. (n=3, unpaired t test). 	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AM) to measure calcium mobilization, a direct output of proximal BCR 
signaling, in DLBCL cells treated with vehicle or PU-H71. These experiments 
revealed profound suppression of BCR-induced calcium flux in both GCB and 
ABC DLBCL cells pretreated with PU-H71. 
2.3.3 Basal and BCR-induced NF-κB activity 
After determining that teHsp90 function is required for proximal BCR signaling 
through calcium signaling, we sought to determine if impairment in BCR 
signaling was associated with downstream effects on NF-κB activity. To test 
this, we used the Ramos-blue cell line – a B cell lymphoma cell line 
engineered to express an NF-κB responsive reporter encoding alkaline 
phosphatase – to measure basal and BCR-induced NF-κB activity. In cells 
	  
Figure 3.8 Calcium mobilization in DLBCL cells requires teHsp90 
function. OCI-Ly1, OCI-Ly7, HBL-1 and TMD8 cells were treated with vehicle 
or PU-H71 (1 µM, 2h), then incubated with a fluorescent calcium indicator 
(Fluo-4 AM, 2 µM, 30min) then washed and resuspended in calcium free PBS. 
Calcium release was measured over time by flow cytometry before and after 
BCR stimulation (IgM+IgG 10 µg/mL at 120sec). n=3, unpaired t test. 
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treated with PU-H71 we observed a significant decrease in NF-κB reporter 
activity (p=0.02) and even more profound suppression of NF-κB activity after 
BCR stimulation of these cells (p=0.01 Figure 3.9A). 
 
Next we wanted to determine if NF-κB activity in DLBCLs was teHsp90 
dependent. To test this, we transfected OCI-Ly1 and HBL-1 cells with the NF-
κB reporter vector (NF-κB)5-luc2CP-pGL4 which contains five copies of the 
NF-κB consensus-response element and a destabilized firefly luciferase. 
Exposure to PU-H71 diminished basal NF-κB reporter activity in transfected 
HBL-1 and OCI-Ly1 cells 50% and 90%, respectively (p=0.0001, Figure 3.9B). 
BCR stimulation with IgM+IgG induced a 1.5- and 3-fold increase in NF-κB 
reporter activity in HBL-1 and OCI-Ly1 cells, respectively (p=0.01, p<0.0001, 
Figure 3.9B). Further, treatment with PU-H71 decreased BCR-induced NF-κB 
reporter activity to 80% of control levels (p=0.02) in HBL-1 cells and just 5% of 
control reporter activity in OCI-Ly1 cells (p<0.0001, Figure 3.9B). 
 
2.3.4 PU-H71 atteanuates signaling of lateral pathways within the BCR 
signaling network 
Our proteomics assays identified teHsp90 client proteins within the BCR 
signaling network that are lateral to the canonical BCR signaling pathway such 
as PI3K, mTOR, MAPK, JNK1/2 and ERK1/2. Because teHsp90 is required 
not only for the stability was also the activity of its client proteins, we wondered 
teHsp90 function was required for activity of these signaling effectors. To test 
this, we treated ABC DLBCL cells with PU-H71 at short timepoints before total 
client protein degradation is observed and assayed for client activity by 
phospho-immunoblot. We observed a time-dependent decrease in ERK 
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Figure 3.9 Basal and BCR-induced NF-κB activity require teHsp90 
function. (A) Ramos-blue cells were treated with vehicle, PU-H71 (1 µM), 
IgM+IgG (10 µg/mL) or PU-H71 and IgM+IgG (6h). NF-κB reporter activity was 
measured by colorimetric assay. Unpaired t-test. (B) HBL-1 and OCI-Ly1 
transfected with an NF-κB luciferase reporter were treated with PU-H71 (1 
µM), IgM+IgG (10 µg/mL) or both (16h) and luciferase activity was assayed. 
Unpaired t test. 	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activity in three ABC DLBCL cell lines and a dramatic time-dependent 
reduction of AKT activity in HBL-1 cells (Figure 3.10). 
2.4 Model of teHsp90 regulation of BCR signaling 
Collectively, these data reveal a critical role for teHsp90 stress complexes in 
BCR signaling. In the presence of PU-H71, the BCR exhibits deficient 
localization to lipid rafts while concomitantly, SYK and BTK build up on 
CD79A, the signaling moiety of the BCR, unable to recycle. Due to these 
effects, and possibly due to additional effects on other signaling mediators of 
this pathway, there is a resultant loss of calcium flux and NF-κB activity in 
DLBCL cells (Figure 3.11). 
	  
Figure 3.10 PU-H71 induces inhibition of PI3K and ERK pathways in ABC 
DLBCL. HBL-1, TMD8 and OCI-Ly10 cells were exposed to vehicle or PU-
H71 for increasing times as indicated. Lysates were subjected to imunoblotting 
with anitibodies to pAKT S473 and AKT (A) or pERK T202/Y204 and ERK (B). 
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3. Discussion 
In this chapter, the scope of previously known Hsp90 functions has been 
expanded to include binding and facilitating signaling through the BCR 
signalosome. This function is linked to the tumor-enriched fraction of Hsp90 
complexes that can be selectively targeted using the small molecule PU-H71. 
PU-H71 binds tightly to teHsp90 complexes in an ATP-competitive manner 
(58). PU-H71 causes teHsp90 to become “locked” in a client protein bound 
configuration (58). Consistent with the locking effect of PU-H71, exposure of 
DLBCL cells to this compound resulted in more stable association of CD79A 
with SYK and BTK as well as disruption of the association of BCR complexes 
with lipid rafts. Collectively, these data are consistent with the notion that 
	  
Figure 3.11 Model of PU-H71 effects on BCR signaling at multiple nodes. 
Inhibition of teHsp90 induces broad attenuation of BCR signaling at multiple 
nodes including BCR signalosome dynamic recycling, proximal kinase activity, 
calcium flux and NF-κB activity. 
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teHsp90 in some way is required to maintain proper configuration of the BCR 
signalosome. Moreover, the components of the BCR must dynamically recycle 
their configuration to promote signaling; teHsp90 may chaperone these 
dynamics. As actual membrane to cytoplasm vesicle recycling of the BCR is 
only mildly disturbed by PU-H71 (Figure 3.6), the actions of PU-H71 might be 
more intimately associated with perturbation of membrane complex protein 
interaction dynamics. Clearly, in depth structural studies will be required in the 
future to understand these mechanisms.  
 
Hsp90 isoforms are known to associate with membrane bound proteins such 
as the BCR. For example, Hsp90N has been shown to contain a putative 
myristylation sequence, which may explain its membrane localization (207). In 
T cells, Hsp90 is required for the membrane association of the Src-family 
kinase Lck (208). Like many other Hsp90 client proteins, activating mutations 
in Lck increase its dependence on Hsp90 (208). CD79, the signaling moiety of 
the BCR is often mutated in ABC DLBCLs, resulting in chronic activation of the 
pathway (150). Though the enzymes of BCR signaling, SYK, BTK and PLCγ2 
do not harbor activating mutations, they form the BCR signalosome with CD79 
and exhibit increased activity in the ABC DLBCLs. The biochemical and 
functional dependence of the BCR signalosome on teHsp90 is consistent with 
the previously demonstrated requirement of teHsp90 to maintain signaling 
pathways aberrantly activated in human leukemia, lymphoma and solid tumor 
cells (38, 58, 74, 92). In fact, in avian cells, knockout of Hsp90β was shown to 
induce multiple defects in BCR signaling including reduction in surface 
expression of IgM and basal and serum-induced BCR signaling (209). The 
data herein confirm and underline that teHsp90 stress complexes carry out 
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specific biochemical functions beyond the classical protein stability and folding 
functions attributed to Hsp90. Future biochemical approaches probing deeper 
into the role of teHsp90 in membrane biology and lipid raft functions may 
provide further insights into the mechanisms described herein. 
 
An important concept that emerges from this work is the notion of teHsp90 as 
a general facilitator of BCR signaling. The pharmacoproteomic assays 
described in chapter one indicated extensive interaction of teHsp90 with BCR 
signaling proteins at multiple levels and throughout multiple branches of the 
BCR signaling network. These findings correspond with the overall attenuation 
of BCR signaling, calcium flux and NF-κB activity induced by PU-H71. 
Moreover, we show that teHsp90 function is required not only for the canonical 
BCR signaling pathway, but also for lateral signaling pathways within the BCR 
signaling network including PI3K/AKT and MEK/ERK. 
 
It is worth noting that teHsp90 also associates with BCR components in GCB-
type DLBCL cells. In fact, many of the nodes of BCR signaling that are 
attenuated with PU-H71 are affected equally in GCB and ABC DLBCL cells. It 
has been shown that GCB DLBCL cells exhibit tonic BCR activity and can be 
targeted by signaling inhibitors such as SYK inhibitors (23). Hence it is 
possible that teHsp90 is important for both tonic BCR activity in lymphoma 
cells as well as chronic active signaling that is more characteristic of ABC-
DLBCLs. These data suggest that PU-H71 is a viable therapeutic in the ABC 
subtype of DLBCL and may affect cell viability through a different mechanism 
than has been described in GCB DLBCL (38), suggesting the possibility of 
patient-stratified combinatorial therapies. 
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4. Materials and methods 
Cell lines and reagents 
The DLBCL cell lines OCI-Ly1 and OCI-Ly7 were grown in Iscove’s Modified 
Dulbecco’s Medium (IMDM) containing 10% FBS and supplemented with 
peniciliin and streptomycin. OCI-Ly10 was gorwn in IMDM with 20% FBS and 
penicillin and streptomycin. The DLBCL cell lines HBL-1 and TMD8 were 
grown in medium containing 90% RPMI and 10% FBS supplemented with L-
glutamine, HEPES and penicillin and streptomycin. PU-H71 was synthesized 
as previously reported (58). Filipin was purchased from Sigma. All human IgM 
and IgG was purchased from Jackson Immunoresearch. The following 
antibodies were used: phospho-SYK Y352 #2701, phospho-BTK Y223 #5082, 
BTK clone D3H5, phospho-PLCγ2 Y759 #3874, phospho-AKT S473 #9271, 
AKT #2920, phospho-ERK T202/Y204 #9106, and ERK1/2 #9102 (Cell 
Signaling Technology), SYK clone 4D10, PLCγ2 clone Q-20 (Santa Cruz 
Biotechnology), Hsp90 ab13495 (Abcam), β-actin clone AC-15 (Sigma 
Aldrich). 
 
Cell lysis for immunoblot 
Cells were counted for viability using Trypan blue dye exclusion, then 
centrifuged at 1500 rpm for 5 minutes at room temperature and resuspended 
in fresh medium at a concentration of 2 x 106/mL. For lysis, cells were 
centrifuged for 5 minutes at 1500 rpm at room temperature, then washed with 
1X PBS and centrifuged again. Cells were lysed in lysis buffer (10 mM 
HEPES-KOH pH 7.9, 1.5 mM MgCl2, 10 mM KCl, freshly prepared 1.5 mM 
NaMoO4, 1% Triton-X, 0.5 mM PMSF, and protease and phosphatase 
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inhibitors) on ice for 15 minutes, vortexed on high for 15 seconds and 
centrifuged at 14,000 rpm for 10 minutes at 4°C. Supernatants were measured 
for protein concentration, mixed with 5X SDS loading buffer and resolved by 
standard immunoblotting procedures. 
 
Subcellular Fractionation 
To isolate membrane fractions, 100 x 106 cells were harvested, washed in 1X 
PBS, and then incubated for 30 minutes at 4°C in 2 mL of hypotonic buffer (42 
mM KCl, 10 mM HEPES pH 7.4, 5 mM MgCL2). Cells were homogenized by 
three rounds of freeze-thawing and centrifuged at 250xg for 10 minutes to 
remove nuclei and intact cells. The supernatant was centrifugred at 150,000xg 
for 30 minutes at 4°C to separate cytoplasm from the membrane fraction. The 
membrane fraction was lysed (1% Triton X-100 in 10 mM Tris-HCl pH7.5, 150 
mM NaCl and 5 mM EDTA with protease inhibitors) for 30 minutes on ice. 
Protein concentration of fractions were quantified using DC Biorad Assay and 
equal amounts were resolved by standard SDS-PAGE immunoblotting 
procedure. 
 
Total Internal Reflection Fluorescent Microscopy 
Coverslip preparation: Before plating, coverslips were coated with 3.5 µg of 
Cell-Tak (BD Biosciences) in 300 µL of neutral buffer solution (0.1M sodium 
bicarbonate pH 8.0) by rocking for 30 minutes at room temperature, then 
washing twice with distilled water and allowing the coverslips to air dry. After 
plating, coverslips were centrifuged at 1000 rpm to allow cells to adhere.  
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Cell plating and treatment: Cells were treated as indicated on the coverslips. 
After treatment, media was aspirated and cells were fixed by adding warm 
PHEMO fixative (3.7% formaldehyde, 0.05% glutaraldehyde, 0.5% Triton X-
100 in 0.068M PIPES, 0.025M HEPES, 0.015M EGTANa2, 0.003M 
MgCl26H2O, 10% DMSO pH 6.8) and incubating for 10 minutes at room 
temperature. Coverslips were washed 3 times in 1X PBS by shaking gently for 
5 minutes. Cells were blocked with 5% normal goat serum in 1X PBS for 10 
minutes at room temperature. 
 
Immunostaining: Primary antibodies were diluted in 5% normal goat serum in 
1X PBS and incubated overnight at 4°C (Hsp90 Abcam #ab13945, SYK clone 
4D10 Santa Cruz Biotechnology) or for 1 hour at room temperature 
(AlexaFluor 488 goat anti-human IgM, Molecular Probes A21215) then 
washed 3 times with 1X PBS. Fluorescent conjugated secondary antibodies 
(Molecular Probes) were diluted in 5% normal goat serum in 1X PBS, added to 
coverslips and incubated for 1 hour at room temperature in the dark, with 
shaking. This process was repeated for the second antibody. 
 
Imaging: Cells were imaged on a Nikon TiE inverted microscope with a 100X 
Apo TIRF objective lens (1.49 NA) and NIS-Elements software using Agilent 
lasers (488nM = 47mW, 568nM = 58mW) and the Andor Neo sCMOS camera. 
 
Immunoprecipitation 
Cells were plated at a concentration of 2 x 106/mL and treated with vehicle or 
PU-H71. Cells were harvested, washed with PBS, and lysed in IP buffer (25 
mM HEPES pH 7.5, 150 mM NaCl, 0.2% NP-40, 10% glycerol, 1 mM DTT, 20 
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mM NaMoO4 and protease inhibitors) for 30 minutes on ice, and then 
centrifuged at 14,000 rpm for 15 minutes at 4°C to remove insoluble proteins. 
Protein concentration of supernatants was measured using the DC Protein 
Assay Kit (Biorad). Input (10 µg) was saved at -20°C. For each IP, 1 mg of 
protein was precleared for 1 hour at 4°C with 20 µL of Protein G Sepharose 
beads (Sigma) that were pre-washed three times with IP buffer to remove 
ethanol. Precleared lysates were precipitated with 10 µg of either αCD79A 
(Clone HM47, Santa Cruz Biotechnology) or mouse IgG (Abcam ab14813), 
tumbling overnight at 4°C. Additional Sepharose Protein G beads were 
blocked overnight tumbling with 1 µg/µL BSA at 4°C. The next day, Sepharose 
Protein G beads were washed three times with fresh IP buffer and 20 µL was 
added to each IP and tumbled for one hour at 4°C. IP-bead conjugates were 
washed three times in IP buffer, resuspended in 20 µL 2X SDS loading buffer, 
and boiled for 5 minutes at 100°C. 5X SDS loading buffer was added to inputs 
to achieve a final concentration of 1X and they were boiled for 5 minutes at 
100°C. Inputs and immunoprecipitates were resolved by standard 
immunoblotting procedure and blotted with antibodies to CD79A (clone HM47, 
Santa Cruz biotechnology), SYK (clone DH35, Santa Cruz Biotechnology), 
BTK (clone D3H5, Cell Signaling Technology), and Hsp90 (Abcam #ab13495). 
 
BCR-lipid raft colocalization 
Cells were treated with vehicle or PU-H71 for 4 hours. After washing with PBS, 
cells were fixed with 4% paraformaldehyde/0.1% glutaraldehyde/1X PBS for 
20 minutes at room temperature. Cells were stained with 10 µg/mL F(ab’)2 
fragment goat anti-human IgM (Jackson ImmunoResearch 109-006-129) in 
0.1% BSA/0.02% sodium azide/1X PBS for 20 minutes at room temperature. 
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After washing with PBS, cells were stained with 1:1000 Alexa Fluor 647 
conjugated donkey anti-goat IgG (Invitrogen A21447) in 0.1% BSA/0.02% 
sodium azide/1X PBS for 20 minutes at room temperature in the dark. Cells 
were washed with PBS, and then incubated with 50 µg/mL filipin (Cayman 
Cheimcal #70440) in PBS for 1 hour at room temperature in the dark. Cells 
were next affixed to slides by cytocentifugation at 1300 rpm for 5 minutes and 
mounted with ProLong Gold antifade reagent (Life Technologies). Cells were 
imaged at 60X using the Fluoview FV10i confocal microscope (Olympus) and 
analyzed for colocalization using the JACoP plug-in (206) with ImageJ (NIH). 
 
Flow cytometry based BCR internalization assay 
Cells were pretreated with vehicle or 1 µM PU-H71 for two hours. To prepare 
cells, they were first washed with cold 1X PBS, then incubated with 10 µg/mL 
F(ab’)2 fragment goat anti-human IgM (Jackson ImmunoResearch 109-006-
129) at a concentration of 2x106 for 30 minutes at 4°C. Cells were washed 
twice with cold 1X PBS and incubated at 37°C for 0-20 minutes. Internalization 
was stopped by transferring tubes to ice and adding cold 1% FBS in 1X PBS. 
To detect receptors remaining on the surface, cells were stained with 
AlexaFluor 647 donkey anti-goat IgG (Molecular Probes A21447) in 1% FBS in 
1X PBS for 20 minutes at room temperature. Cells were washed twice with 1% 
FBS in 1X PBS, then fixed in 1% paraformaldehyde. Data was acquired on 
MacsQuant flow cytometer (Miltenyi Biotec) and analyzed using FlowJo 
software package (TreeStar). 
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Multicolor intracellular phosphoflow cytometry 
Cells were plated at 2 x 106/mL and treated with vehicle or 1 µM PU-H71 for 1 
hour at 37°C. 10 µg/mL IgG + IgM (Jackson Immunoresearch 309-005-107) 
was added to treated cells and incubated at 37°C for 15 minutes. Cells were 
fixed by adding BD Phosflow Fix Buffer I (BD Biosciences) directly to culture 
medium and incubating for 15 minutes at 37°C. Cells were harvested into 
eppendorf tubes, centrifuged at 1500 rpm for 5 minutes at room temperature, 
then permeabilized by adding 250 µL of cold BD Phosflow Perm Buffer III (BD 
Biosciences) and incubating on ice for 30 minutes, after which 500 µL of 
wash/stain buffer (1% FBS, 0.09% NaN3 in 1X PBS) was added. Cells were 
centrifuged at 1500 rpm for 5 minutes at 4°C, and each sample was divided for 
staining in equal amounts of either fluorescent-conjugated specific phospho-
antibodies (AlexaFluor 488 Mouse anti-SYK pY348 clone I120-722 catalog 
number 560081, PE Mous anti-BTK pY223 clone N35-86 catalog number 
562753, AlexaFluor 647 Mouse anti-PLCγ2 pY759 clone K86-689.37 catalog 
number 558498, BD Biosciences) or matching isotype controls (AlexaFluor 
488 Mouse IgG1 K2317666, PE Mouse IgG1 K 551436, AlexaFluor 647 
Mouse IgG1 K 557783 BD Biosciences) in wash/stain buffer on ice. Data was 
acquired on MacsQuant flow cytometer (Miltenyi Biotec) and analyzed using 
FlowJo software package (TreeStar). 
 
Calcium Release 
Cells were plated at 2 x 106 and treated with vehicle or 1 µM PU-H71 for 2 
hours at 37°C, then incubated with 2 µM Fluo 4 AM (Invitrogen #F14217) for 
30 minutes at 37°C. Fluorescent indicator was washed out cells with fresh 
media, and cells recovered for 30 minutes at 37°C. Cells were collected in 
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PBS without calcium, and fluorescence was measured on an LSR-II flow 
cytometer (BD Biosciences) for 2 minutes. The tube was removed for the 
addition of 10 µg/mL of IgG + IgM (Jackson Immunoresearch 309-005-107) 
and one second of vortexing to mix. The tube was replaced and fluorescence 
measurement continued for at least 5 more minutes. Calcium release was 
quantified using FlowJo software package (TreeStar) as area under the curve 
for the first four minutes. 
 
Ramos-blue NF-κB alkaline phosphatase reporter activity assay 
Ramos-blue cells (Invivogen) were grown in IMDM containing 10% FBS, 
supplemented with L-glutamine, penicillin and streptomycin, 100 µg/mL 
normocin and 100 µg/mL zeocin. To assay, cells were resuspended in medium 
without selective antibiotics at a concentration of 2 x 106/mL, plated in a flat-
bottom 96-well plate and treated with vehicle, 1 µM PU-H71, 10 µg/mL IgG + 
IgM (Jackson Immunoresearch 309-005-107), or PU-H71 and IgG + IgM for 6 
hours at 37°C. Following treatment, 40 µL of medium from each treated well 
was transferred to a new flat-bottom 96-well plate and incubated with 160 µL 
of QUANTI-Blue reagent overnight at 37°C. Alkaline phosphatase activity was 
measured by colorimetic assay at 630 nM with the Synergy4 plate reader 
(BioTek). 
 
NF-κB luciferase reporter assays 
In HBL-1 and OCI-Ly1, 1 µg of (NF-κB)5-Luc2CP-pGL4 per 5 x 106 cells were 
transfected using nucleofection (Amaxa, Lonza). Eight hours after transfection, 
cells were plated at 2 x 106 cells/mL and treated with vehicle, 1 µM PU-H71, 
10 µg/mL IgG + IgM (Jackson Immunoresearch 309-005-107), or PU-H71 and 
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IgG + IgM for 16 hours at 37°C. Cells were harvested and submitted to Dual-
Glow luciferase assays following manufacturer’s protocol (Promega). Briefly, 
cells were lysed in 20 µL 1X passive lysis buffer by rocking at room 
temperature for 20 minutes. 5µL of each sample was added to a white-walled 
96 well plate and 50 µL of Luciferase Assay buffer was added before 
luminescence was read by plate reader (Synergy4, BioTek). 
 
Statistical analysis 
Two-tailed unpaired t test was used unless otherwise stated. All statistical 
analyses were carried out using Prism software (GraphPad). 
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CHAPTER FOUR 
Concomitant inhibition of teHsp90 and the BCR pathway combines to 
inhibit the growth of DLBCLs 
 
1. Introduction 
For many therapeutic targets in cancer achieving a high degree of suppression 
is imperative to obtain maximal anti-tumor effect. Complex signaling networks 
like the BCR pathway tend to branch out in many directions, making their 
complete suppression a challenge. Moreover, complete suppression of the 
target of a specific inhibitor must be balanced against its off-target effects that 
can become increasingly problematic with higher doses that may be needed 
for therapeutic effect. Even if maximal target inhibition is achieved, exposure to 
targeted compounds over time can lead to acquired resistance in tumors 
through mutations that prevent drug binding or activate the pathway through 
another protein in the pathway. 
 
Inhibition of teHsp90 can resolve many of the issues with targeted therapy by 
simultaneously inhibiting many signaling nodes within multiple pathways. As 
shown above, PU-H71 inhibition of teHsp90 accomplishes broad attenuation 
of BCR signaling at multiple nodes, weakening the BCR signaling pathway, 
and potentially, signaling network. This mechanism of action makes teHsp90 
inhibition an ideal platform for rational combination therapies. By combining 
broad signaling attenuation with focused attack on a key node of oncogenic 
signaling required for cancer cell survival, maximal target and pathway 
suppression can be achieved, resulting in increased anti-tumor effect. 
Specifically, inhibition of teHsp90 and its client proteins can synergize to kill 
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cancer cells. For example, the combination of PU-H71 and RI-BPI, a 
peptidomimetic inhibitor of BCL6, the main oncogene in DLBCL and client of 
teHsp90, synergizes to kill these cancers in vitro, in vivo and ex vivo (194). 
Further, combined exposure to PU-H71 and obatoclax, an inhibitor of BCL2-
family proteins such as MCL-1, a teHsp90 client in PEL, synergized to kill 
these lymphoma cells (74). After identifying and validating several components 
of the BCR pathway as clients of teHsp90 in DLBCL, we hypothesized that 
combinatorial exposure of DLBCLs to the BCR-attenuating activity of PU-H71 
together with specific targeted BCR pathway inhibitors would result in additive 
or synergistic growth inhibition through maximal suppression of the BCR 
signaling pathway. 
 
2. Results 
2.1 PU-H71 and inhibitors of BCR signaling synergize to inhibit growth of 
DLBCL cells 
We set out to determine if PU-H71 synergizes with BCR pathway inhibitors. 
We selected a panel of BCR pathway inhibitors, prioritizing inhibitors within 
each class by clinical relevance. The inhibitors chosen for investigation and 
their targets are listed in Table 4.1. 
 
In order to determine the dosages and schedules that could induce dose-
dependent growth inhibition in DLBCL cells, we exposed a panel of DLBCL 
cell lines to vehicle or a dose curve of each of the BCR pathway inhibitors and 
assayed for cell viability. We determined that buparlisib and MI-2 could be 
administered for 48 hours to induce dose-dependent growth inhibition. 
However R406, ibrutinib and sotrastaurin, had to be administered for 96 hours, 
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adding drug twice, at 0 and 48 hours to induce the same growth inhibition 
effect. This slower onset of growth inhibition likely results because these 
inhibitors are cytostatic, not cytotoxic, and therefore they require more time to 
induce an effect on cell viability. Our results confirm reports that GCB DLBCLs 
are resistant to ibrutinib, MI-2 and sotrastaurin but are sensitive to R406 and 
buparlisib. Although PU-H71 causes dose-dependent growth inhibition within 
48 hours of a single dose, we also determined the doses required for longer 
exposures to be used for combination experiments. Dose curves of each 
individual drug in a panel of DLBCL cell lines are shown in Figure 4.1. 
 
Table 4.1 Inhibitors selected for combination treatments and their 
targets 
Inhibitor Target 
R406 SYK 
Ibrutinib (PCI-32765) BTK 
Buparlisib (BKM120) PI3K (pan) 
MI-2 MALT1 
Sotastaurin (AEB071) PKCβ 
 
In order to determine the growth inhibition effect of PU-H71 in combination 
with this panel of BCR pathway inhibitors, we exposed a panel of DLBCL cell 
lines to vehicle, PU-H71, each BCR pathway inhibitor, or the PU-H71-BCR 
combination. Each drug was administered at 6 doses in 1:2 dilutions, and the 
combination was administered in constant ratio. We calculated combination 
effect using the algorithm of Chou and Talalay (210). All of these combinations 
showed synergistic (combination index (CI) value below 0.9) or additive (CI 
value between 0.9 and 1.1) effect at concentrations sufficient to inhibit growth 
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75% (GI75, Figure 4.2). The most potently synergistic combination was PU-
H71 and ibrutinib, with marked synergy observed in three ABC DLBCL cell 
lines (CI GI95 < 0.4, Figure 4.2).  
 
We observed that GCB DLBCL cell lines respond to some inhibitors of the 
BCR pathway. In order to determine the combination effect of PU-H71 with 
inhibitors of the BCR pathway, we exposed GCB DLBCL cell lines to PU-H71, 
BCR pathway inhibitors or the combination and assayed for viability. For drug 
combinations where the cell lines respond to the individual BCR pathway 
inhibitors, we calculated combination effect using the algorithm of Chou and 
Talalay (210). We observed additive or weakly synergistic effect in 
combinations of PU-H71 with R406 and buparlisib (Figure 4.3A). In order to 
calculate combinatorial using this method, a dose effect curve for each 
individual drug is required. For combinations involving BCR pathway inhibitors 
that show resistance in GCB DLBCL cell lines, we plotted dose-effect curves 
of each drug and the combination. We observed no difference between the 
fraction of growth inhibited in the PU-H71 and combination conditions (Figure 
4.3B). 
 
Similarly, the ABC DLBCL cell line OCI-Ly3 has an activating mutation in 
CARD11, which acts downstream of the BCR signalosome. As such, this cell 
line is resistant to BCR pathway inhibitors that act upstream of the CBM 
complex. Though these cells are sensitive to PU-H71, we observed no 
increased growth inhibition effect when combined with ibrutinib or sotrastaurin 
(Figure 4.3B). Taken together, our data suggest that synergy with PU-H71 
requires sensitivity to BCR pathway inhibitors. 
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Figure 4.1 Dose response curves of BCR pathway inhibitors in DLBCL 
cell lines. A panel of DLBCL cell lines was exposed to PU-H71 and various 
BCR pathway inhibitors in two different schedules and assayed for viability. 
Growth inhibition was calculated by normalizing drug treated cells to vehicle 
treated cells. 	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Because teHsp90 inhibition disrupts BTK activity, we wondered if the 
combinatorial effect of PU-H71 with ibrutinib was linked to more powerful 
inhibition of BTK activity. To test this, we exposed three independent ABC 
DLBCL cell lines to vehicle, PU-H71, ibrutinib or the combination for 2 hours 
and measured BTK activity by phospho-immunoblot. The combination of PU-
H71 and ibrutinib resulted in additive inhibition of BTK activity (Figure 4.4A).
	  
Figure 4.2 PU-H71 combination treatment with BCR pathway inhibitors 
additively or synergistically kills ABC DLBCLs. A panel of ABC DLBCL cell 
lines were exposed to PU-H71, a BCR pathway inhibitor or the combination 
and assayed for cell viability. Dose curves for single and combination drug 
exposures were plotted and combination index (CI) values were calculated 
using the algorithm of Chou and Talalay (208). Average CI value (n≥3) ± SEM 
is plotted. CI value between 0.9 and 1.1 represents additive effect. CI value 
below 0.9 represents synergistic effect. 	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Figure 4.3 Combination effect of PU-H71 with BCR pathway inhibitors in 
GCB DLBCLs and a CARD11 mutant ABC DLBCL cell line, OCI-Ly3. (A) 
Average CI ± SEM (n=3) values of OCI-Ly1 and OCI-Ly7 cells exposed to PU-
H71, a BCR pathway inhibitor or the combination and assayed for cell viability. 
(B) Dose-effect curves of OCI-Ly1, OCI-Ly7 and OCI-Ly3 cells exposed to PU-
H71, a BCR pathway inhibitor or the combination and assayed for cell viability. 	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teHsp90 inhibition disrupts NF-κB activity in DLBCL (Figure 3.9), and BTK 
activity is required for NF-κB activity in ABC DLBCLs. We wondered if the PU-
H71-ibrutinib combination more potently suppresses BCR signaling 
downstream of BTK activity. To test this we used p65 ELISA to measure NF-
κB activity in nuclear lysates of two ABC DLBCL cell lines treated with average 
GI50 values of PU-H71, ibrutinib or the combination for 24 hours. At the doses 
tested, single drugs induced a modest reduction in p65 DNA binding activity. 
In contrast, the PU-H71-ibrutinib combination significantly decreased p65 
activity by 60% in HBL-1 and TMD8 cells in an additive manner (p=0.03, 
p=0.04, respectively, Figure 4.4B). 
 
As an orthogonal method to test this notion, we used HBL-1 cells transfected 
with the NF-κB reporter vector (NF-κB)5-luc2CP-pGL4 which contains five 
copies of the NF-κB consensus-response element and a destabilized firefly 
luciferase. Exposure to PU-H71 or ibrutinib decreased NF-κB activity by 65% 
and 80%, respectively (p=0.0006, p<0.0001, respectively, Figure 4.4C) The 
PU-H71-ibrutinib combination decreased NF-κB luciferase activity by 90%, 
and this reduction was significantly more than either ibrutinib or PU-H71 alone 
(p=0.013, Figure 4.4C). Taken together, our data suggest that the synergistic 
growth inhibition observed in the PU-H71-ibrutinib combination results from 
maximal suppression of the BCR pathway, exemplified in BTK and NF-κB 
activity. 
 
2.2 Ibrutinib enhances PU-H71 anti-lymphoma effect in vivo 
The PU-H71-ibrutinib combination is particularly suited for clinical translation 
because PU-H71 is in clinical trials and ibrutinib is an FDA-approved drug, 
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Figure 4.4 PU-H71 and ibrutinib combine to maximally suppress BCR 
signaling. (A) Lysates of HBL-1, TMD8 and OCI-Ly10 cells treated as 
indicated were subjected to immunoblotting. Relative protein abundance was 
quantified using densitometry. Data are presented as mean with SEM, 
unpaired t test. (B) Nuclear lysates of treated HBL-1 and TMD8 cells were 
probed for p65 DNA binding activity with TransAM ELISA. Data are presented 
as mean with SEM n=3, unpaired t test. (C) HBL-1 cells transfected with an 
NF-κB luciferase reporter were treated for 16h and assayed for luciferase 
activity. Data represents average with sem, unpaired t test. 
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prompting us to further investigate this combination treatment in ABC DLBCL 
in vivo. Concentrations of PU-H71 determined in this work to inhibit BCR 
signaling components (~1 µM) are readily achieved in the tumors of patients 
using well tolerated doses in our phase I studies (193). We established HBL-1 
and TMD8 xenografts in non-obese diabetic/severe combined 
immunodeficiency (NOD-SCID) mice. After tumors reached an average of 100 
mm3 in volume, mice were randomized to receive vehicle, ibrutinib, PU-H71 or 
the combination. TMD8 and HBL-1 mice were treated daily with 12.5 mg/kg 
ibrutinib (ad libitum), 75 mg/kg PU-H71 (intraperitoneal injection) or the 
combination for 11-13 days (Figure 4.5A). As a single agent, ibrutinib did not 
significantly inhibit the growth of both TMD8 and HBL-1 xenograft models 
compared to vehicle. PU-H71 significantly reduced tumor growth in both TMD8 
and HBL-1 xenografts as a single agent compared to vehicle (p<0.0001 and 
p=0.03, respectively). The PU-H71-ibrutinib combination suppressed TMD8 
and HBL-1 xenograft growth significantly more than ibrutinib (p<0.0001) or PU-
H71 alone (p=0.0045 and p=0.008, respectively, Figure 4.5B, C).  
 
In order to determine in the combination effect observed in vivo was linked to 
more potent inhibition of BTK activity as was observed in cell lines, we 
established new HBL-1 and TMD8 xenografts in NOD-SCID mice (n=3/group) 
and administered a single dose of vehicle, ibrutinib, PU-H71 or the 
combination. Mice were sacrificed 24 hours after treatment, and tumors were 
harvested to assay for BTK activity by phospho-immunoblot (Figure 4.6A). In 
TMD8 xenografts, single doses of each drug had little effect on BTK 
phosphorylation. In marked contrast, the ibrutinib-PU-H71 combination 
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Figure 4.5 PU-H71 potentiates response to ibrutinib in ABC DLBCL in 
vivo. (A) NOD-SCID mice were subcutaneously injected with 106 HBL-1 or 
TMD8 cells in 1:1 matrigel:PBS. Tumors grew until palpable, and daily 
treatment began. (B and C) Left panels: Tumor growth plots of TM8 (B) and 
HBL-1 (C) xenografted mice treated with vehicle (saline, black circles), 
ibrutinib (12.5 mg/kg in chow, ad libitum, blue squares, Ibr), PU-H71 (75 mg/kg 
intraperitoneal injection, red triangles, PU) or the combination (purple 
triangles). Right panels: Growth of each tumor was measured as area under 
the curve. Average tumor growth is represented on the y-axis (tumor volume 
(mm3)/time (days)). Mean ± SEM, Mann-Whitney U test. 
	   92	  
significantly suppressed BTK phosphorylation (p=0.04). In HBL-1 xenografts, 
we observed modest inhibition of BTK in both single agent treatments, but 
these effects were not statistically significant. In animals treated with the 
ibrutinib-PU-H71 combination, however, we observed a 75% inhibition of 
active BTK in their HBL-1 ABC DLBCL tumors (p=0.039, Figure 4.6B) 
Collectively, the ibrutinib-PU-H71 combination therapy results in enhanced 
anti-lymphoma effect in vivo, and pharmacodynamics studies indicated that 
this was associated with more potent suppression of BTK activity. 
 
	  
Figure 4.6 PU-H71 and ibrutinib combine to maximally suppress BTK 
signaling in vivo. (A) NOD-SCID mice were xenografted with TMD8 or HBL-1 
cells as described and treated for 24 hours. (B) Lysates of tumors harvested 
from experiments in A were subjected to immunoblot with the antibodies 
indicated. The relative abundance of phosphor-BTK to total BTK was 
quantified using densitometry. Mean ± SEM, unpaired t-test. 	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In order to determine if the PU-H71-ibrutinib combination treatment is toxic, we 
treated C57 Black mice (n=3/group) for 12 days with vehicle, ibrutinib (12.5 
mg/kg ad libitum), PU-H71 (75 mg/kg, intraperitoneal injection) or the 
combination. A second cohort of mice (n=3/group) were maintained without 
drug exposure for an additional 14 days to serve as a “washout” comparison 
group for any observed toxicities in the “treatment” group (Figure 4.7). Animals 
were weighed daily and sacrificed 24 hours after the last treatment followed by 
a comprehensive histopathology and molecular analysis. 
 
	  
Figure 4.7 Ibrutinib and PU-H71 combination is non-toxic in mice. (A) C57 
Black6 mice (n=6/group until day 13) were treated with vehicle, ibrutinib (12.5 
mg/kg/d ad libitum), PU-H71 (75 mg/kg/d i.p.) or the combination for 12 days. 
Animals were weighed every other day. Half of each group (n=3) was 
sacrificed after treatment for microscopic analysis of organs and blood. The 
other half (n=3) continued untreated for two weeks to serve as a “washout” 
group. Animals were weighed every other day until sacrifice for organ and 
blood analysis.   	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Animals treated with PU-H71 lost a significant amount of weight compared to 
vehicle and ibrutinib treated animals, but this effect was reversed during the 
washout period (Figure 4.7). Further, there was no evidence of hematologic, 
renal or hepatic toxicity, as determined by blood counts, blood chemistry, and 
liver function testing (Table 4.2). No microscopic evidence of toxicity was 
observed in the intestines, kidneys, spleens, livers, lungs or hearts harvested 
from any of the mice. The bone marrow control and ibrutinib treated mice 
revealed no specific pathological findings, although there was evidence of 
hypocellularity in 1/3 PU-H71 only and 2/3 combined treatment mice. Bone 
marrow in all PU-H71 and combination treated mice in the washout group 
revealed normocellular bone marrow, demonstrating that the observed toxicity 
is reversible when drug is removed. 
 
2.3 PU-H71 and ibrutinib combination yields enhanced killing of human 
non-GCB DLCL patient samples ex vivo. 
Whereas lymphoma cell lines have been used extensively for pre-clinical 
studies, it is important to underline that these cells may not be fully 
representative of primary human tumors. We obtained viable primary non-GCB 
DLBCL specimens classified by Hans immunohistochemistry criteria (211). 
These patient specimens were plated on a feeder layer of irradiated HK cells 
and treated with vehicle, 2 nM ibrutinib, 1 µM PU-H71 or the combination for 
48 hours. Cell viability was measured by flow cytometry scoring CD20+ B cells 
for Annexin V and DAPI to determine their viability. 
 
In patient sample 6128 the PU-H71-ibrutinib combination treatment produced 
significantly enhanced lymphoma-killing effect. In non-GCB DLBCL patient 
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sample 6938, the PU-H71-ibrutinib combination resulted in even more potent 
killing relative to each drug alone, although statistics could not be generated 
since there were insufficient cells to perform multiple replicates (Figure 4.8). In 
five other non-GCB DLBCL patient samples tested, we observed no response 
to ibrutinib as a single agent. Although these samples responded to PU-H71, 
the PU-H71-ibrutinib combination effect observed was equivalent with the 
effect of PU-H71 as a single agent (Figure 4.8). This result mirrors effects 
observed in cell lines and may be explained by mutational status of BCR 
proteins in these patient specimens. Collectively, the efficacy of the PU-H71-
ibrutinib combination in vitro, in vivo and in human patient samples ex vivo 
supports the rationale for translation of this combination therapy in human 
patients.  
	  
Figure 4.8 PU-H71 and ibrutinib combine to more powerfully kill primary 
non-GCB DLBCLs ex vivo. Human non-GCB DLBCL patient samples were 
cultured on an irradiated HK cell feeder layer. Cells were exposed to vehicle, 
ibrutinib (2nM every 24 hours, blue bar), PU-H71 (1μM, red bar) or the 
combination (purple bar) for 48 hours. Cell viability (represented as 
percentage of vehicle-treated cells) was measured using flow cytometry and 
is plotted on the y-axis. Live cells are defined as CD20+/CD3- cells that are 
Annexin V/DAPI double negative. Sample 6128 was tested in 2 biological 
replicates, unpaired t test. Other samples were tested in 2 technical 
replicates. Data are presented as mean with SEM. 
	   97	  
3. Discussion 
The BCR pathway is well appreciated as a therapeutic target in ABC DLBCLs. 
Targeting with selective inhibitors against BTK, SYK, PI3K, PKCβ or MALT1 
can suppress the growth of ABC DLBCL cells. While potentially effective, the 
BCR pathway is not linear, but more of an interconnected network of signaling 
pathways. As a result, targeted therapies against single proteins may not 
globally suppress all aspects of BCR signaling. For example, a phase II clinical 
trial of ibrutinib monotherapy in ABC DLBCL patients revealed a 41% overall 
response rate (181). Moreover, single agent targeted therapies can give rise to 
resistance. In fact, acquired resistance to ibrutinib has been described in 
patients with somatic mutations in BTK that block inhibitor binding and in 
PLCγ2 that activate the pathway downstream of the drug (190, 191). Because 
of these challenges, single agent targeted therapies are unlikely to be curative 
in a molecularly heterogeneous disease such as ABC DLBCL. Indeed, a 
clinical trial of ibrutinib in combination with R-CHOP immunochemotherapy 
achieved 100% ORR with 60% CR in a clinical study of ABC DLBCL patients 
(189). However, because R-CHOP treatment is associated with toxicities, 
immune suppression and secondary malignancies, improved regimens are 
needed for these patients. 
 
Based on this and the data herein, we propose the clinical translation of 
regimens that combine the BCR “attenuator” effects of PU-H71 discovered 
through our pharmacoproteomics approach and described in chapter three, 
with the more punctual and incisive specific targeted approach represented by 
ibrutinib and other similar agents. Indeed, the combination of PU-H71 with 
ibrutinib showed robust synergy in cell lines, and cooperative effect in animal 
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models and primary human DLBCL cells. In further confirmation of our data, a 
recent high throughput combinatorial screening study identified Hsp90 
inhibitors as one of several classes of drugs that cooperate with ibrutinib to kill 
ABC DLBCLs (192).  
 
Synergy between PU-H71 and ibrutinib was associated with more potent 
suppression of BTK and NF-κB activation. Why exactly the combination of PU-
H71 with ibrutinib yielded the most potent synergy in inhibiting ABC DLBCL 
growth remains unclear and could be due to the potency of ibrutinib, the 
dependence of ABC DLBCLs on BTK, the dependence of BTK on teHsp90 in 
ABC DLBCLs or some combination of these reasons. Naturally, suppression 
of other teHsp90 client actions could also contribute to these synergistic 
effects, such as its effects on the BCL6 transcription factor protein (38). If 
anything, this adds to the potential appeal of using PU-H71 to anchor 
combinatorial therapy for DLBCL. By more greatly inhibiting signaling 
pathways critically required for ABC DLBCL survival, this combination therapy 
can not only increase the efficacy of treatment, but also potentially minimize 
the occurrence of resistance through the inhibition of compensatory proteins or 
pathways. In fact, Hsp90 inhibition has been shown to overcome resistance to 
a number of targeted therapies. Perhaps if given as a frontline treatment, this 
combination regimen could decrease the emergence of resistance later on.  
 
An important finding in this work is the lack of toxicity observed in animals 
exposed to the combination of PU-H71 and ibrutinib. This suggests that this 
combination would be well tolerated in humans. Moreover, because PU-H71 
selectively inhibits the pool of teHsp90 that maintains an oncogenic 
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phenotype, we expect that targeted therapies combined with PU-H71 will 
exhibit less toxicity than conventional chemotherapy in patients. PU-H71 is 
currently completing phase I testing in humans and will be available for phase 
II studies as a single agent or for rational combination therapy. We expect 
such studies to yield improved efficacy in humans compared to single BCR 
agent targeted therapy. 
 
In many of the human ABC DLBCL patient samples tested ex vivo, we 
observed no response to ibrutinib, and, as we observed in viability assays 
using cell lines that do not respond to ibrutinib as a single agent, the 
combination effect is no greater than that of PU-H71 alone. These patient 
samples may harbor mutations in CARD11 or A20 downstream of BTK, 
preventing their response to ibrutinib, or may require a higher dose to induce 
some effect. For example, HBL-1 and TMD8 cell lines both respond to 
ibrutinib, but with a 10-fold difference in GI50 values (4 nM and 0.4 nM, 
respectively). Information about the mutational status of these patients and 
further testing with other doses of ibrutinib may yield further insights about 
their response profiles. This information may also provide valuable information 
for patient stratification for PU-H71-ibrutinib combination therapy. 
 
While ABC DLBCL is the more aggressive subtype with poorer prognosis and 
greater need for novel therapeutic regimens, some of the combination 
treatments tested herein yielded combinatorial effect in ABC and GCB 
DLBCLs. Information about patient mutational status may prove useful in 
patient stratification of the PU-H71-ibrutinib combination and other PU-H71 
anchored combination therapies for DLBCL patients from both subtypes. 
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Taken together, the efficacy of the PU-H71-ibrutinib combination in vitro, in 
vivo and in human patient samples ex vivo provides the rationale for 
translation of this combination therapy in human patients. Other combinatorial 
regimens anchored with PU-H71 may provide better treatment options for all 
DLBCL patients. 
 
4. Materials and methods 
Cell lines and reagents 
The DLBCL cell lines OCI-Ly1 and OCI-Ly7 were grown in Iscove’s Modified 
Dulbecco’s Medium (IMDM) containing 10% FBS and supplemented with 
peniciliin and streptomycin. OCI-Ly10 was grown in IMDM with 20% FBS and 
penicillin and streptomycin. The DLBCL cell lines HBL-1 and TMD8 were 
grown in medium containing 90% RPMI and 10% FBS supplemented with L-
glutamine, HEPES and penicillin and streptomycin. OCI-Ly3 was grown in 
RPMI with 20% FBS supplemented with L-glutamine, HEPES and penicillin 
and streptomycin. PU-H71 was synthesized as previously reported (58). 
Ibrutinib drug and chow was provided by Pharmacyclics. R406 and 
sotrastaurin were purchased from Selleck Chemicals. MI-2 was purchased 
from AMRI. BKM120 was a gift of the Cantley lab. Antibodies to phospho-BTK 
Y223, and BTK were purchased from Cell Signaling Technology. Antibody to 
β-actin (clone AC-15) was purchased from Sigma Aldrich. 
  
Cell lysis for immunoblot 
Cells were treated at a concentration of 2 x 106/mL, harvested, washed with 
PBS, and resuspended in lysis buffer (10 mM HEPES-KOH pH7.9, 1.5 mM 
MgCl2, 10 mM KCl, freshly prepared 1.5 mM Na2MoO4, 1% Triton-X, 0.5 mM 
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PMSF, protease and phosphatase inhibitors). Lysates were mixed with 5X 
SDS loading buffer (1X final) and resolved according to standard 
immunoblotting procedure. 
 
Cell viability assays and synergy experiments 
DLBCL cell lines were played in 384-well white-wall plates at concentrations 
sufficient to keep untreated cells in exponential growth during the time of drug 
exposure (50,000/mL for 96 hour exposure, 100,000/mL for 48 hour 
exposure). Cells were treated with 6 doses of each drug of combination in 
technical triplicates. For combination treatments, cells were exposed to a dose 
curve of each drug or their combination in constant ratio. After treatment, a 
standard curve was made using vehicle treated cells. Cell viability was 
determined by an ATP luminescent method (CellTiter-Glo, Promega). 
Luminescence was measured with the Synergy4 microplate reader (BioTek). 
Cell viability of drug-treated cells was normalized to vehicle treated controls. 
Compusyn software (Biosoft) was used to plot dose effect curves and 
calculate combination index values. 
 
NF-κB luciferase reporter assays 
In HBL-1, 1 µg of (NF-κB)5-Luc2CP-pGL4 per 5 x 106 cells were transfected 
using nucleofection (Amaxa, Lonza). Eight hours after transfection, cells were 
plated at 2 x 106 cells/mL and treated with vehicle, 4 nM ibrutinib, 1 µM PU-
H71 or the combination for 16 hours at 37°C. Cells were harvested and 
submitted to Dual-Glow luciferase assays following manufacturer’s protocol 
(Promega). Briefly, cells were lysed in 20 µL 1X passive lysis buffer by rocking 
at room temperature for 20 minutes. 5µL of each sample was added to a 
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white-walled 96 well plate and 50 µL of Luciferase Assay buffer was added 
before luminescence was read with the Synergy4 plate reader (BioTek). 
 
NF-κB ELISA 
HBL-1 and TMD8 cells were treated with vehicle, 2 nM ibrutinib, 1 µM PU-H71 
or the combination for 24 hours, then harvested and washed in ice-cold PBS. 
To extract nuclear lysates, cell pellets were resuspended in 1 mL ice-cold 
hypotonic buffer (20 mM HEPES pH 7.5, 5 mM NaF, 10 µM Na2MoO4, 0.1 mM 
EDTA) and incubated on ice for 15 minute until the addition of 50 µL 10% NP-
40. Tubes were vortexed vigorously for 10 seconds. Cells were checked for 
lysis of the cell membrane under the microscope. Homogenates were 
centrifuged for 30 seconds at 4°C. Supernatants (cytoplasmic fractions) were 
removed and saved at -80°C. Pellet were resuspended in 50 µL Complete 
Lysis Buffer (prepared according to manufacturer’s instructions) and rocked 
gently on ice for 30 minutes on a shaking platform. Tubes were centrifuged for 
10 minutes at 14,000 x g at 4°C. Supernatants (nuclear extracts) were saved 
and measured for protein concentration using the DC Biorad Assay. 
 
Following extraction, 30 µL of Complete Binding Buffer and 5 µg of nuclear 
extract diluted in 20 µL of Complete Lysis Buffer was added to each well. 
Complete Lysis Buffer was used as a negative control and 5 µg of provided 
Raji nuclear extract was used as a positive control. Samples were tested in 
technical duplicate. Nuclear extracts bound to probes for one hour at room 
temperature with shaking, and then wells were washed three times with wash 
buffer. p65 primary antibody bound to extracts in wells for one hour at room 
temperature followed by three washes with wash buffer. Wells were incubated 
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with secondary antibody for one hour at room temperature and then washed 
three times with wash buffer. To develop, 100 µL of developing solution was 
added to all wells being used and incubated for 2 minutes at room temperature 
protected from direct light. Then 100 µL of stop solution was added and 
absorbance was read at 450 nM with the Synergy4 plate reader within 5 
minutes (BioTek). 
 
Xenografts 
Eight week old NOD-SCID mice were injected subcutanesouly with 106 cells in 
1:1 PBS:matrigel. Tumors grew until palpable (2-3 wekks) and then treatment 
began. Mice were injected intraperitoneally with vehicle or 75 mg/kg PU-H71 
daily. Ibrutinib was administered via chow at a dose of 12.5 mg/kg/d ad libitum. 
Control and PU-H71 treated mice were given vehicle chow. Tumors were 
measured with digital calipers and animals were weighed every other day. 
Animals were sacrificed after treatment and tumors were weighed and 
harvested for molecular investigation. 
 
Toxicity 
Eight-week old C57 Black 6 mice were treated with vehicle, ibrutinib (12.5 
mg/kg/d ad libitum), PU-H71 (75 mg/kg/d i.p. injection) or PU-H71-ibrutinib 
combination for 12 days (n=6/group). Animals were weighed every other day. 
After 12 days, 3 animals per group were sacrificed and organs (intestine, 
spleen, kidney, liver, lung, heart and bone marrow) were harvested. Tissues 
were fixed in 4% formalin and then washed in 70% ethanol and sent for 
sectioning and staining with H&E. Stained tissues were microscopically 
analyzed by specialized pathologists. Blood was also collected at the time of 
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sacrifice for complete blood count test and chemical analysis. The second half 
of each group continued without drug for 14 days to serve as a “washout” 
group. After 14 days, these animals were sacrificed and their organs and 
blood subjected to the same investigations. 
 
Primary cell treatment 
We obtained deidentified human tissues in accordance with and approval from 
the Institutional Review Board of the New York Presbyterian Hospital. Samples 
were classified as non-GCB DLBCL using Hans classification 
(immunohistochemistry for BCL6, CD10 and MUM1 with 30% cutoff for 
positivity). Single-cell suspensions from lymph node biopsies were thawed and 
resuspended in Advanced RPMI supplemented with 20% human serum, 
Glutamax (2X), glycine (5 mM) and penicillin and streptomycin. Cell number 
and viability was determined by counting with Trypan blue. Irradiated HK cells 
(2000 rad) in DMEM supplemented with 10% FBS and penicillin and 
streptomycin were adhered to tissue culture plates at 37°C. Media was 
aspirated and patient samples were plated on the HK feeder layer. Samples 
were exposed to vehicle, ibrutinib (2 nM, daily), PU-H71 (1 µM) or the 
combination for 48 hours, and then stained with FITC-conjugated anti-CD20, 
PE-Cy7-conjugated anti-CD3 and APC-conjugated anti-Annexin V anti-human 
antibodies (BD Biosciences). DAPI was used for the exclusion of dead cells. 
Data was acquired on a MacsQuant flow cytometer (Miltenyi Biotec) and 
analyzed using FlowJo software package (TreeStar). CD20+/CD3- cells that 
were Annexin V/DAPI double negative were considered live. 
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Study Approval 
Deidentified patient tissues were obtained in accordance with and approval 
from the Institutional Review Board (IRB) of the Weill Cornell Medical College. 
The Research Animal Resource Center (RARC) of the Weill Cornell Medical 
College approved all mouse procedures. 
 
Statistical Analysis 
Two-tailed unpaired t test was used unless otherwise stated. Specifically, two-
tailed Mann-Whitney U test was used for xenografts growth experiment 
analysis. All statistical analyses were carried out using Prism software 
(Graphpad). 
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CHAPTER FIVE 
Additional approaches to Identify combinatorial treatments for ABC 
DLBCL 
 
1. Introduction 
Intracellular signaling pathways drive cell decisions including proliferation, 
growth and survival. The amplitude and duration of pathway activation is 
precisely controlled by complex regulatory mechanisms. Because they 
regulate such important aspects of cell fate, these pathways are often hijacked 
by activating mutations in signaling activators or deletions of signaling 
repressors in tumor cells attempting to achieve immortality. Targeted therapies 
against these transformed proteins and pathways involve the use of small 
molecule inhibitors of these corrupted signaling effectors to induce apoptosis 
in tumor cells. The improved precision of targeted therapies over conventional 
chemotherapy is expected to induce increased efficacy and decreased toxicity 
in patients.. 
 
However, clinical translation of targeted therapies faces several challenges. 
Prolonged exposure to single drugs can result in acquired drug resistance, and 
targeted therapies administered as single agents often produce low response 
rates. The modest efficacy of single agent targeted therapy results in part from 
the complexity of cellular signaling. Most signaling pathways do not exist in a 
vacuum, but rather interact with numerous others to form larger signaling 
networks with pathway crosstalk and compensatory circuits that can allow 
tumors to bypass single nodes of inhibition. Moreover, many tumors are 
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molecularly and cellularly heterogeneous. Therefore, it is widely accepted that 
single agent therapy is unlikely to be curative in cancer. 
 
By simultaneously inhibiting multiple nodes within a broader signaling network, 
therapies combining multiple inhibitors can completely disable oncogenic 
signaling and induce more potent and durable responses. The identification of 
combinations of two or more drugs that cooperate to extinguish oncogenic 
signaling pathways and networks is critical to improve treatment options for 
cancer patients. The high complexity of signaling networks and available 
inhibitors precludes merely guessing which drug combinations will elicit an 
enhanced combined effect. In this work, we have described a 
pharmacoproteomic method using teHsp90 inhibitors as bait to identify client 
proteins as potential partners for therapeutic synergy. In this chapter, we 
describe additional methods to identify combination treatments using ABC 
DLBCL as a model system, computational and hypothesis-driven. 
 
ABC DLBCL is characterized by chronic activation of the BCR signaling 
pathway. These cells are addicted to constitutive activation of survival signals 
in this pathway including that of NF-κB activation. Many small molecule 
inhibitors of this pathway have been developed and result in killing of ABC 
DLBCLs in vitro and in vivo (140, 150, 164, 165). However, in human patients, 
these targeted therapies evoke limited responses most likely because of the 
inherent complexity of the BCR signaling network. Combination therapies that 
target multiple nodes of the BCR signaling network may improve patient 
responses. Rather than large, costly experimental screens, an accurate in 
silico model of BCR signaling in ABC DLBCLs may serve as a computational 
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platform in which to test hundreds of combinations for efficacy. This model 
may also illuminate combinations that hypothesis-driven experiments would 
not immediately consider as actionable. 
 
Hypothesis-driven experiments are another approach to identify effective 
combination therapies for ABC DLBCL. The availability of specific, potent 
inhibitors of different inhibitors of the BCR pathway is truly an embarrassment 
of riches. Further, numerous ABC DLBCL cell lines are well characterized for 
the mutational status of their BCR pathway proteins. Armed with these tools, 
one can make educated guesses about which agents might more effectively 
shut down BCR signaling by disrupting known redundancies and feedback 
loops within the pathway. 
 
In this chapter we present data of different combination treatments for ABC 
DLBCL predicted by an in silico model of BCR signaling and through the 
hypothesis-driven rational prediction. We observed differential combination 
growth arrest effects depending on which nodes of the BCR signaling network 
were concomitantly inhibited and discuss the relevance for future rational 
design of therapeutic combinations. 
 
2. Results 
2.1 A virtual B cell lymphoma model to predict effective combination 
therapy for ABC DLBCL 
A detailed kinetic model of the BCR signaling network parameterized by 
biochemistry assays and protein concentration quantification was constructed 
by our collaborator, Wei Du (unpublished). The BCR signaling network was 
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curated by gathering experimentally validated protein-protein interactions from 
the literature. The resultant network includes three major signaling pathways 
downstream of the BCR, namely NF-κB, PI3K/AKT and RAF/RAS/ERK. The 
model was then parameterized using protein binding affinity and enzyme 
reaction kinetics measured by published in vitro biochemistry assays and 
cellular protein concentrations. 
 
Next, a tumor growth model was constructed in order to simulate the effect of 
various small molecule inhibitors of BCR signaling on ABC DLBCL viability and 
to compare simulation results with published combinatorial drug response 
data. The model was constructed in the ABC DLBCL cell line TMD8 because 
of the extensive drug combinatorial data available for it. Published drug-effect 
viability data from experiments of ibrutinib combined with inhibitors of NF-κB, 
MEK or AKT was used to parameterize the growth model (192). 
 
Using this model, Du predicted synergistic growth inhibition effect across all 
possible target pairs. The BCR protein pair predicted to show the most 
synergistic growth inhibition effect when simultaneously inhibited was SYK and 
PI3K. To test this in vitro, we used three ABC DLBCL cell lines – HBL-1, 
TMD8 and OCI-Ly10 – exposed to PRT062607 (a SYK inhibitor), a panel of 
PI3K inhibitors BKM120 (pan-PI3K), BYL719 (PI3Kα), CAL101 (idelalisib, 
PI3Kδ) and GDC0941 (PI3Kα/δ) or SYK in combination with each of these 
inhibitors and assayed for cell viability. We observed additive and less than 
additive growth inhibition effect in most of these combinations (Figure 5.1A), 
matching the model’s prediction of weakly synergistic combination effect 
(~0.86). The pair predicted to be the next most synergistic was BTK-PI3K; this 
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therapeutic combination has been shown to exhibit synergistic growth 
inhibition of ABC DLBCLs (192). 
 
 
	  
Figure 5.1 SYK and PKCβ inhibitors combine with PI3K inhibition to 
arrest growth of ABC DLBCL cell lines. HBL-1, TMD8 and OCI-Ly10 cells 
were exposed to a SYK inhibitor (A), a PKCβ inhibitor (B), a panel of PI3K 
inhibitors or the combination and assayed for viability. Combination index 
values were calculated and plotted here. TMD8, OCI-Ly10 (A) GI75, (B)GI90 
HBL-1 (A) GI75 (B)GI50 (B) n=2, average ± SEM. 
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Next, we investigated the PKCβ-PI3K pair, predicted to be the fourth most 
synergistic possible combination. To test the combination effect, we exposed 
HBL-1, TMD8 and Ly10 cells to sotrastaurin, a panel of PI3K inhibitors and the 
combinations and assayed for viability. Nearly all of these combinations 
proved to be synergistic with combination index values between 0.5 and 0.8 
for BKM120, 0.4 and 0.7 for BYL719 and 0.5 and 1.0 for GDC0941. STN 
combined with CAL101 produced remarkable synergy in TMD8 and OCI-Ly10 
cells (CI GI90 0.15, 0.11 respectively, Figure 5.1B) far surpassing the model’s 
predictions (CI ~0.88), and suggesting that with more modifications the in silico 
model may be a very useful tool in identifying effective combination treatments 
for ABC DLBCL. 
 
2.2 Hypothesis-driven combination therapies with MALT1 inhibition for 
ABC DLBCL 
Recently, our lab developed MI-2, a first in class MALT1 inhibitor, and 
demonstrated that it selectively kills ABC DLBCL cells in vitro, in vivo and 
human patient samples ex vivo (165). Because single agents are unlikely to be 
curative in this molecularly heterogeneous disease, we wondered if combining 
MI-2 with other BCR pathway inhibitors might induce greater suppression of 
BCR signaling, leading to additive or synergistic killing of ABC DLBCLs. To 
test this hypothesis we exposed ABC DLBCL cells to MI-2, BCR pathway 
inhibitors, or the combination and assayed for viability. We observed additive 
and weakly synergistic combination effect in these experiments (Figure 5.2) In 
other experiments combining MI-2 with various PI3K inhibitors in these cell 
lines, we have observed a more synergistic effect (CI GI75 between 0.15 and 
0.71). MI-2 combined with the MEK inhibitor selumetinib is also highly 
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synergistic in these cell lines (CI GI75 between 0.3 and 0.4). Other BCR 
pathway targeted therapies may combine with MI-2 to reveal more effective 
combinatorial growth inhibition.  
 
3. Discussion 
An accurate computational model of BCR signaling that reflects tumor growth 
and inhibition in the presence of different pathway inhibitors would be of great 
use in predicting combination therapies for ABC DLBCL. Such a model would 
provide broad applicability, as cellular testing may be limited to cell line tested 
and not translatable to highly variable patient tumors. Moreover, thousands of 
experiments can be performed quickly and affordably in silico. In vitro 
experiments of combined SYK-PI3K inhibition resulted in additive growth 
arrest effect, matching the model’s prediction. The PKCβ-PI3K target pair was 
predicted to have additive growth inhibition effect, but when tested in vitro 
showed astonishingly synergistic growth inhibition. Limitations of the 
	  
Figure 5.2 MI-2 combines with BCR pathway inhibitors to inhibit ABC 
DLBCL growth.	  HBL-1, TMD8 and OCI-Ly10 ABC DLBCL cells were exposed 
to MI-2, BCR pathway inhibitors, or the combination and assayed for viability. 
Combination index values were calculated and are plotted here as average ± 
SEM.	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computational model such including LYN as only a positive regulator of BCR 
signaling may need to be addressed before the model can accurately predict 
protein pairs for combination therapy. 
 
While in vitro experimental data did not validate the in silico predictions, it did 
reveal a very highly synergistic protein pair for therapeutic combination – 
PKCβ and PI3K. Of note, combined inhibition of MI-2 and PI3-K also produces 
highly synergistic growth arrest effects in ABC DLBCL cells. The synergistic 
effect of combined BTK and PI3K inhibition has also been demonstrated (192). 
Each of these therapeutic combinations includes inhibition of PI3K and a 
protein of the canonical BCR signaling pathway – PKCβ, BTK or MALT1. 
Combined PI3K-IKK inhibition will likely induce synergistic growth arrest in 
these cells as well. In effect, these treatments achieve inhibition of two 
signaling branches within the larger BCR signaling network. This effect is 
echoed in MI-2-selumetinib treatments. By contrast, hitting the same pathway 
twice – i.e. MI-2 combined with R406, ibrutinib or sotrastaurin – elicits additive 
growth inhibition effect. It should be mentioned that SYK-PI3K dual inhibition 
blocks multiple branches while achieving additive growth inhibition effect. This 
may be due to the selectivity and potency of the inhibitors. 
 
In this work we demonstrated that the PU-H71-ibrutinib therapeutic 
combination results in maximal inhibition of BTK signaling propagated 
downstream through NF-κB activity. We also showed that PU-H71 attenuates 
kinase function of ERK and AKT, perhaps the prototypical teHsp90 client. The 
basis of PU-H71 synergy with ibrutinib compared to additivity with other BCR 
pathway inhibitors may be due to the potency and specificity of the inhibitors 
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used. However, the added inhibition of the PI3K and ERK lateral pathways 
within the BCR signaling network by PU-H71 undoubtedly contributes to the 
marked synergy of the PU-H71-ibrutinib combination treatment in ABC 
DLBCL. Taken together, these experiments show that dual inhibition of a 
signaling pathway results in additive growth inhibition, but inhibition of multiple 
branches within a signaling network is required for synergistic growth arrest. 
 
4. Materials and methods 
Cell lines and reagents 
The DLBCL cell lines HBL-1 and TMD8 were grown in medium containing 90% 
RPMI and 10% FBS supplemented with L-glutamine, HEPES and penicillin 
and streptomycin. OCI-Ly10 was grown in IMDM with 20% FBS and penicillin 
and streptomycin. Ibrutinib was provided by Pharmacyclics. PRT062607, 
CAL101, and sotrastaurin were purchased from Selleck Chemicals. MI-2 was 
purchased from AMRI. BYL719, BKM120 and GDC0941 were gifts of the 
Cantley lab. 
 
Cell viability assays and synergy experiments 
DLBCL cell lines were played in 384-well white-wall plates at concentrations 
sufficient to keep untreated cells in exponential growth during the time of drug 
exposure. Cells were treated with 6 doses of each drug of combination in 
technical triplicates. For combination treatments, cells were exposed to a dose 
curve of each drug or their combination in constant ratio. After treatment, a 
standard curve was made using vehicle treated cells. Cell viability was 
determined by an ATP luminescent method (CellTiter-Glo, Promega). 
Luminescence was measured with the Synergy4 microplate reader (BioTek). 
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Cell viability of drug-treated cells was normalized to vehicle treated controls. 
Compusyn software (Biosoft) was used to plot dose effect curves and 
calculate combination index values. 
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